```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 11:33:30 ON 19 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 19 May 2004  VOL 140 ISS 21
FILE LAST UPDATED: 18 May 2004  (20040518/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=>
=>

=> d stat que
L19             STR
```



```
VAR G1=C/N
VAR G2=C/N
VAR G3=S/C
NODE ATTRIBUTES:
NSPEC   IS RC     AT   8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L20             STR
```



VAR G1=C/N
VAR G2=C/N
VAR G3=S/C
NODE ATTRIBUTES:
NSPEC IS RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L21 STR



VAR G1=C/N
VAR G2=C/N
VAR G3=S/C
NODE ATTRIBUTES:
NSPEC IS RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L22 STR



VAR G1=C/N
VAR G2=C/N
VAR G3=S/C
NODE ATTRIBUTES:
NSPEC IS RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

L24 1196 SEA FILE=REGISTRY SSS FUL L19 OR L20 OR L21 OR L22
L25 STR



VAR G1=CH/N
VAR G2=C/N
VAR G3=S/CH2
NODE ATTRIBUTES:
NSPEC IS RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L26 1006 SEA FILE=REGISTRY SUB=L24 SSS FUL (L19 OR L20 OR L21 OR L22)
NOT L25
L27 STR



VAR G1=CH/N
VAR G2=C/N
VAR G3=S/CH2
NODE ATTRIBUTES:
NSPEC IS RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L28 295 SEA FILE=REGISTRY SUB=L26 SSS FUL L27
L29 71 SEA FILE=HCAPLUS ABB=ON PLU=ON L28
L30 61 SEA FILE=HCAPLUS ABB=ON PLU=ON L29 AND PD=<AUGUST 16, 2002

=>
=>

=> d ibib abs hitrn 130 1-61

L30 ANSWER 1 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:887694 HCAPLUS
DOCUMENT NUMBER: 139:358745
TITLE: Polyamine analogues as therapeutic and diagnostic agents
INVENTOR(S): Vermeulin, Nicolaas M. J.; O'Day, Christine L.; Webb, Heather K.; Burns, Mark R.; Bergstrom, Donald E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 78 pp., Cont.-in-part of U.S. Ser. No. 396,523.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6646149	B1	20031111	US 2000-584175	20000531
WO 9903823	A2	19990128	WO 1998-US14896	19980715 <--
WO 9903823	A3	19990408		
W: AL, AM, AU, AZ, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6172261	B1	20010109	US 1999-341400	19990903 <--
WO 2001092218	A2	20011206	WO 2001-US17795	20010531 <--
WO 2001092218	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1317424	A2	20030611	EP 2001-946044	20010531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509845	T2	20040402	JP 2002-500833	20010531

PRIORITY APPLN. INFO.:

US 1997-52586P	P	19970715
US 1997-65728P	P	19971114
US 1998-85538P	P	19980515
WO 1998-US14896	A2	19980715
US 1999-341400	A2	19990903
US 1999-396523	A2	19990915
US 2000-584175	A	20000531
WO 2001-US17795	W	20010531

AB Novel "bispolyamine" inhibitor compds. of polyamine transport are disclosed. These compds. are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. These compds. display desirable activities both for diagnostic and research assays and therapy.

IT **220221-36-3**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel polyamine transport-inhibiting polyamine analogs as therapeutic and diagnostic agents)

L30 ANSWER 2 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:555486 HCAPLUS
DOCUMENT NUMBER: 137:125099
TITLE: Cyclo[d]azepane derivatives as farnesyl transferase inhibitors
INVENTOR(S): Casara, Patrick; Le Diguarher, Thierry; Dorey, Gilbert; Hickman, John; Pierre, Alain; Tucker, Gordon; Guilbaud, Nicolas; Fauchere, Jean-Luc; Ortuno, Jean-Claude
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057258	A1	20020725	WO 2002-FR149	20020116 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
FR 2819512	A1	20020719	FR 2001-639	20010118 <--
FR 2819512	B1	20030221		

PRIORITY APPLN. INFO.: FR 2001-639 A 20010118
OTHER SOURCE(S): MARPAT 137:125099
GI



I



II

AB Title compds. I [X = alkylene, CO, S(O)n, S(O)nA1, COA1, A1S(O)nA2, A1COA2; Y = (un)substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl; W = CO, CH2; R1, R2 = H, (un)substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl; T = CHR3, NR3, NR3CO; V = H, (un)substituted aryl, heteroaryl; A1, A2 = alkylene; A3 = (CR4R5)p; R3 = H, (un)substituted alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl; R4, R5 = H, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, aralkyl, heteroaralkyl, heterocyclylalkyl; B = atoms required to complete an (un)substituted aryl or heteroaryl ring; n = 0-2;

p = 0-4] were prepd. for use as farnesyl transferase inhibitors in the treatment of cancers, neurofibromatosis type 1 and restenosis after angioplasty or vascular surgery. Thus, 1-amino-3-(2-methylbenzyl)-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one was prepd. from glyoxylic acid in 6 steps and was treated with 1-(4-cyanobenzyl)-1H-imidazole-5 carboxaldehyde to give the title compd. II.

IT **443927-03-5P 443927-04-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cyclo[d]azepane derivs. as farnesyl transferase inhibitors)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 3 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:555485 HCAPLUS
DOCUMENT NUMBER: 137:125098
TITLE: Cyclo[c]azepane derivatives for use as farnesyltransferase inhibitors
INVENTOR(S): Casara, Patrick; Le Diguarher, Thierry; Dorey, Gilbert; Hickman, John; Pierre, Alain; Tucker, Gordon; Guilbaud, Nicolas; Fauchere, Jean-Luc; Ortuno, Jean-Claude
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057257	A1	20020725	WO 2002-FR148	20020116 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
FR 2819510	A1	20020719	FR 2001-642	20010118 <--
FR 2819510	B1	20031031		

PRIORITY APPLN. INFO.: FR 2001-642 A 20010118
OTHER SOURCE(S): MARPAT 137:125098
GI



I



II

AB Title compds. I [X = alkylene, CO, S(O)n, S(O)nA1, COA1, A1S(O)nA2, A1COA2; Y = (uN)substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl; W = CO, CH2; R1, R2 = H, (un)substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl; T = CHR3, NR3, NR3CO; V = H, (un)substituted aryl, heteroaryl; A1, A2 = alkylene; A3 = (CR4R5)p; R3 = H, (un)substituted alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl; R4, R5 = H, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, aralkyl, heteroaralkyl, heterocyclylalkyl; B = atoms required to complete an (un)substituted aryl or heteroaryl ring; n = 0-2; p = 0-4] were prepd. for use as farnesyl transferase inhibitors in the treatment of cancers, neurofibromatosis type 1 and restenosis after angioplasty or vascular surgery. Thus, (S)-4-amino-2-(2-methylbenzyl)-1,2,4,5-tetrahydro-3H-2-benzazepin-3-one was prepd. from H-L-Phe-NH2. HCl in 5 steps and was treated with 1-(4-cyanobenzyl)-1H-imidazole-5 carboxaldehyde to give the title compd. II.

IT **443926-06-5P 443926-07-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cyclo[c]azepane derivs. for use as farnesyl transferase inhibitors)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 4 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:553089 HCAPLUS
DOCUMENT NUMBER: 137:109277
TITLE: Preparation of cycloheptenylaminomethylimidazoles as inhibitors of farnesyl protein transferase and geranylgeranyl protein transferase.
INVENTOR(S): Casara, Patrick; Le Diguarher, Thierry; Dorey, Gilbert; Hickman, John; Pierre, Alain; Tucker, Gordon; Guilbaud, Nicolas
PATENT ASSIGNEE(S): Les Laboratoires Servier S.A., Fr.
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1225170	A2	20020724	EP 2002-290101	20020116 <--
EP 1225170	A3	20020828		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
FR 2819509	A1	20020719	FR 2001-641	20010118 <--

FR 2819509	B1	20040416			
US 2002156113	A1	20021024	US 2002-50666	20020116	
US 6638962	B2	20031028			
NO 2002000262	A	20020719	NO 2002-262	20020117	<--
CN 1365973	A	20020828	CN 2002-102042	20020117	
BR 2002000114	A	20021022	BR 2002-114	20020117	
NZ 516684	A	20030630	NZ 2002-516684	20020117	
ZA 2002000471	A	20020722	ZA 2002-471	20020118	<--
AU 2002011937	A5	20020725	AU 2002-11937	20020118	<--
JP 2002265448	A2	20020918	JP 2002-9645	20020118	

PRIORITY APPLN. INFO.: FR 2001-641 A 20010118
OTHER SOURCE(S): MARPAT 137:109277
GI



I

AB Title compds. [I; X = alkylene, CO, SOn, SOnA1, A1COA11, etc.; n = 0-2; A1, A11 = alkylene; Y = (substituted) aryl, heteroaryl, cycloalkyl, heterocycloalkyl; R1-R4 = H, (substituted) aryl, heteroaryl, cycloalkyl, heterocycloalkyl; R1R2, R2R3, R3R4 = bond, atoms to form (heterocyclic) rings; V = H, (substituted) aryl, heteroaryl; A2 = (CR6R16)p; p = 0-4; R6, R16 = H, alkyl, alkenyl, alkynyl, (substituted) aryl, heteroaryl, heterocycloalklyl, etc.; T = CHR5, NR5, NR5CO; R5 = H, (substituted) alkyl, aryl, heteroaryl, aralkyl, heteroaryalkyl], were prepd. Thus, 3-(2-methylphenyl)-2-cyclohepten-1-ylamine (prepn. given), 4-[(5-formyl-1H-imidazol-1-yl)methyl]benzonitrile, and NaHB(OAc)3 were stirred 48 h in dichloroethane to give 4-[[5-[[[3-(2-methylphenyl)-2-cyclohepten-1-yl]amino]methyl]-1H-imidazol-1-yl]methyl]benzonitrile. I inhibited FTPase and GGTase-1 with IC50's in the nanomolar range and in the micromolar range, resp.

IT **443304-29-8P 443304-56-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cycloheptenylaminomethylimidazoles as inhibitors of farnesyl protein transferase and geranylgeranyl protein transferase)

L30 ANSWER 5 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:487577 HCAPLUS
DOCUMENT NUMBER: 137:63420
TITLE: Preparation of lactone ketolide macrolide erythromycin antibiotics
INVENTOR(S): Andreotti, Daniele; Arista, Luca; Biondi, Stefano; Cardullo, Francesca; Damiani, Frederica; Lociuro, Sergio; Marchioro, Carla; Merlo, Giancarlo; Mingardi, Anna; Niccolai, Daniela; Paio, Alfredo; Piga, Elisabetta; Pozzan, Alfonso; Seri, Catia; Tarsi, Luca; Terreni, Silvia; Tibasco, Jessica
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002050091	A1	20020627	WO 2001-GB5665	20011220	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002017277	A5	20020701	AU 2002-17277	20011220	<--
EP 1363925	A1	20031126	EP 2001-271380	20011220	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
NO 2003002846	A	20030820	NO 2003-2846	20030620	
US 2004077557	A1	20040422	US 2003-450893	20031119	
PRIORITY APPLN. INFO.:			GB 2000-31309	A 20001221	
			GB 2001-26276	A 20011101	
			GB 2001-26277	A 20011101	
			WO 2001-GB5665	W 20011220	

OTHER SOURCE(S): MARPAT 137:63420
GI



I

AB The present invention relates to lactone ketolides I wherein R is H, CN, substituted alkyl; R1 is alkyl, alkenyl; R2 is H, hydroxy protecting group; R3 is H, halogen, and pharmaceutically acceptable salts and solvates thereof, to process for their prepn. and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body. Thus, (11S,21R)-3-decladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl-(cyano)-methylene]erythromycin A was prepd. and tested as antibacterial agent against Streptococcus pneumoniae and Streptococcus pyogenes (MIC .ltoreq. 1 .mu.g/mL).

IT **439103-24-9P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of lactone ketolide macrolide erythromycin antibiotics and their use in therapy or prophylaxis of systemic or topical bacterial infections)

IT **245322-47-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of lactone ketolide macrolide erythromycin antibiotics and their use in therapy or prophylaxis of systemic or topical bacterial infections)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 6 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:353439 HCAPLUS
DOCUMENT NUMBER: 136:355242
TITLE: Preparation of phthalazinones as PARP inhibitors
INVENTOR(S): Martin, Niall Morrison Barr; Smith, Graeme Cameron Murray; White, Charles Richard; Newton, Roger Frank; Douglas, Diane Gillian; Eversley, Penny Jane; Vile, Julia
PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK; Maybridge PLC
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036576	A1	20020510	WO 2001-GB4729	20011025 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001095789	A5	20020515	AU 2001-95789	20011025 <--
EP 1330442	A1	20030730	EP 2001-976521	20011025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
GB 2384776	A1	20030806	GB 2003-9190	20011025
GB 2384776	B2	20040303		
BR 2001015062	A	20040217	BR 2001-15062	20011025
NZ 525138	A	20040326	NZ 2001-525138	20011025
JP 2004513121	T2	20040430	JP 2002-539335	20011025
US 2002183325	A1	20021205	US 2001-21506	20011030
NO 2003001498	A	20030402	NO 2003-1498	20030402

PRIORITY APPLN. INFO.:
GB 2000-26505 A 20001030
US 2001-275066P P 20010312
US 2000-245662P P 20001106
WO 2001-GB4729 W 20011025

OTHER SOURCE(S): MARPAT 136:355242
GI



I

AB The title compds. [I; A and B together represent (un)substituted fused arom. ring; R1 = LR3 (wherein L = (CH2)nQm(CH2)p; n, m, p = 0-3, the sum of n, m and p = 1-3; Q = O, S, NH, CO; R3 = (un)substituted C5-20 aryl); R2 = H, (un)substituted C1-7 alkyl, C3-20 heterocyclyl, C5-20 aryl, etc.],

useful for inhibiting the activity of PARP (poly(ADP-ribose)synthase), were prepd. General procedures for synthesis of I were described. Biol. data such as IC50 values against PARP, and DEF which is a ratio of the enhancement of the cell growth inhibition elicited by test compds. in the presence of bleomycin compared to bleomycin alone, were given. E.g., the compd. I [AB = benzo; R1 = 4-chlorobenzyl; R2 = H] showed IC50 of 1.8 .mu.M against PARP, and DEF of 1.9.

IT **420847-48-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phthalazinones as PARP inhibitors)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 7 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:886056 HCAPLUS
DOCUMENT NUMBER: 136:15226
TITLE: Novel polyamine transport-inhibiting polyamine analogues as therapeutic and diagnostic agents
INVENTOR(S): Vermeulin, Nicolaas M. J.; O'day, Christine L.; Webb, Heather K.; Burns, Mark R.; Bergstrom, Donald E.
PATENT ASSIGNEE(S): Oridigm Corporation, USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001092218	A2	20011206	WO 2001-US17795	20010531 <--
WO 2001092218	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6646149	B1	20031111	US 2000-584175	20000531
EP 1317424	A2	20030611	EP 2001-946044	20010531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509845	T2	20040402	JP 2002-500833	20010531

PRIORITY APPLN. INFO.:
US 2000-584175 A 20000531
US 1997-52586P P 19970715
US 1997-65728P P 19971114
US 1998-85538P P 19980515
WO 1998-US14896 A2 19980715
US 1999-341400 A2 19990903
US 1999-396523 A2 19990915
WO 2001-US17795 W 20010531

GI



I

AB Novel "bispolyamine" inhibitor compds. of polyamine transport are disclosed. These compds. are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. These compds. display desirable activities both for diagnostic and research assays and therapy. Most of the spermine dimers that have been tested provided very good Ki for transport inhibition with values under 75 nM. ORI 1236 (I) was the most potent inhibitor with a Ki of 22 nM. The results were generally mirrored in the growth inhibition assay. All of the compds. were synergistic with difluoromethylornithine, a polyamine synthesis inhibitor, with IC50 values of 10 .mu.M or less.

IT **220221-36-3**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel polyamine transport-inhibiting polyamine analogs as therapeutic and diagnostic agents)

L30 ANSWER 8 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:472678 HCAPLUS
DOCUMENT NUMBER: 135:76694
TITLE: Synthesis and herbicidal efficacy of diacyl derivatives of propylene diamine
INVENTOR(S): Hegde, Shridhar G.; Krupa, Daniel M.; Bohn, Joseph A.; Coffen, David L.; Gustafson, Gary R.; Kaplan, Alan P.; Ma, Yuting
PATENT ASSIGNEE(S): Monsanto Co., USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046152	A1	20010628	WO 2000-US32937	20001205 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002052295	A1	20020502	US 2000-730529	20001205 <--
BR 2000016517	A	20020917	BR 2000-16517	20001205
PRIORITY APPLN. INFO.:			US 1999-172802P P	19991221
			WO 2000-US32937 W	20001205

OTHER SOURCE(S): MARPAT 135:76694
GI



I



II

AB Compds. I are claimed [wherein; one of R1a and R1b = Me, CH2OH, or monohalomethyl and the other is hydrogen; X1 = CH2, O or S; m = 0 or 1; R'2 = H, halo or Me; R'3 = halo or halomethyl; R4 = .alpha.-halo or .alpha.,.alpha.-dihalo-alkyl or -(X2)n-R5, where X2 = CH2, O or S; n = 0 or 1; R5 = 5- or 6-membered (substituted)arom. or heterocyclic ring said ring optionally fused to a 5- or 6-membered (substituted) arom. or heterocyclic ring; with a proviso that no more than one ring substituent on the first and second 5- or 6-membered arom. or heterocyclic rings is other than a H, halo, Me, MeO or MeS]. Over 250 synthetic examples are provided. 1,2-Diaminopropane is acylated with 3-(trifluoromethyl)benzoyl chloride (THF, triethylamine, room temp.) to give diamide II in 73% yield. Compds. I were tested for herbicidal efficacy on 16 monocotyledonous and dicotyledonous plant species using a GR80 rating; the concn. at which 80% or greater inhibition obsd. In pre-emergence testing, II had GR80 = 65 - 1000 g/ha on most plant species. The (R)-enantiomer of II (III) was found to have GR80 values typically about one-half those of the racemic mixt. and the (S)-isomer was found to be inactive. Post-emergence testing was also conducted with compds. I. Pre-emergent field trials with III were said to be exhibit acceptable control of several weed species (predominantly dicotyledonous) and was not injurious to corn, sorghum, or soybeans. Application of III in combination with .alpha.-chloroacetamides (e.g. acetochlor) showed greater control over plant species than with either of the herbicides alone indicating a synergistic interaction. A similar phenomena was obsd. for a selected compd. of the invention and glyphosate isopropylammonium salt in a post-emergence test.

IT **346669-13-4P 346669-15-6P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and herbicidal efficacy of racemic and homochiral diacyl derivs. of propylene diamine)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 9 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:265385 HCAPLUS
DOCUMENT NUMBER: 134:295739
TITLE: Preparation of N-aryl-N-(heterocyclylalkyl)piperidinecarboxamides as CCR5 antagonists
INVENTOR(S): Imamura, Shinichi; Hashiguchi, Shohei; Hattori, Taeko; Nishimura, Osamu; Kanzaki, Naoyuki; Baba, Masanori; Sugihara, Yoshihiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 392 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025200	A1	20010412	WO 2000-JP6755	20000929 <--
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000074487	A5	20010510	AU 2000-74487	20000929 <--
JP 2001302633	A2	20011031	JP 2000-302841	20000929 <--
BR 2000014428	A	20020611	BR 2000-14428	20000929 <--
EP 1220842	A1	20020710	EP 2000-962967	20000929 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003048880	A2	20030221	JP 2002-180545	20000929
NO 2002001450	A	20020603	NO 2002-1450	20020322 <--
US 6562978	B1	20030513	US 2002-89374	20020329
ZA 2002002593	A	20030403	ZA 2002-2593	20020403
US 2003114443	A1	20030619	US 2002-273111	20021018

PRIORITY APPLN. INFO.:

JP 1999-282088	A	19991001
JP 2000-46749	A	20000218
JP 2000-302841	A3	20000929
WO 2000-JP6755	W	20000929
US 2002-89374	A3	20020329

OTHER SOURCE(S): MARPAT 134:295739
GI



I

II

AB Title compds. (I) [wherein R1 = H, (un)substituted hydrocarbon or nonarom. heterocycle; R2 = (un)substituted hydrocarbon or nonarom. heterocycle; or R1 and R2 together with A form an (un)substituted heterocycle; A = N or N+(R5).bul.Y-; R5 = hydrocarbon; Y- = counteranion; R3 = (un)substituted (hetero)cycle; n = 0 or 1; R4 = H or (un)substituted hydrocarbon, heterocycle, alkoxy, aryloxy, or amino group; E = (un)substituted divalent aliph. hydrocarbon; G1 = a bond, CO, or SO2; G2 = CO, SO2, NHCO, CONH, or OCO; J = CH or N; Q and R = independently a bond or (un)substituted divalent aliph. hydrocarbon; provided that J = CH when G2 = OCO, that 1 of Q and R is not a bond when the other is a bond, and that each of Q and R is not substituted by oxo group(s) when G1 is a bond; or a salt thereof]

were prepd. as potent chemokine receptor CCR5 antagonists. I are useful for the treatment or prevention of the HIV disease in humans (e.g. AIDS). For example, II.bul.HCl was synthesized in 34% yield in a 2-step process involving addn. of TFA to a soln. of 1-tert-butoxycarbonyl-4-(2-benzothiazolylthio)piperidine in CH2Cl2, followed by addn. of AcCN, 1-acetyl-N-(3-chlorophenyl)-N-(3-chloropropyl)-4-piperidinecarboxamide, K2CO3, and KI to the residue and workup. II.bul.HCl showed 96% inhibition of HIV-1 infection in transformant MAGI-CCR5 cells. In addn., 42 example compds. were tested and gave inhibition rates of 82% to 100% at 1.0 .mu.M in a CCR5 antagonistic activity assay.

IT **333990-73-1P**, N-(3,4-Dichlorophenyl)-N-[3-[4-(4-fluorobenzyl)-1-piperidinyl]propyl]-1-[2-(4-methylphenylthio)-3-pyridylcarbonyl]-4-piperidinecarboxamide trifluoroacetate (1:3)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-aryl-N-(heterocyclylalkyl)piperidinecarboxamide CCR5 antagonists by amidation of N-(arylheterocyclyl)alkylamines or addn. of heterocycles to N-aryl-N-(haloalkyl)piperidinecarboxamides)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 10 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:207925 HCAPLUS
DOCUMENT NUMBER: 134:237682
TITLE: Novel polyamine analogues as therapeutic and diagnostic agents
INVENTOR(S): Vermeulin, Nicholaas M. J.; O'Day, Christine L.; Webb, Heather K.; Burns, Mark R.; Bergstrom, Donald E.
PATENT ASSIGNEE(S): Oridigm Corporation, USA
SOURCE: Eur. Pat. Appl., 140 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1085011	A1	20010321	EP 2000-308049	20000915 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001172244	A2	20010626	JP 2000-282752	20000918 <--

PRIORITY APPLN. INFO.: US 1999-396523 A 19990915

AB Novel inhibitors of polyamine transport having inhibition consts. two orders of magnitude lower than those of known compds. are disclosed. These polyamine analogs are useful pharmaceutical agents for treating disease where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chem. synthetic methods to obtain polyamine analogs are disclosed, including the prodn. of a combinatorial polyamine library. These approaches yield analogs with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.

IT **220221-36-3P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polyamines as therapeutic and diagnostic agents)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 11 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:101134 HCAPLUS
DOCUMENT NUMBER: 134:163045
TITLE: Preparation of benzoxazinecarboxamide derivatives as inhibitors of farnesyltransferase for the treatment of cancer
INVENTOR(S): Achard, Daniel; Jimonet, Patrick; Mailliet, Patrick; Sabuco, Jean-Francois
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009127	A1	20010208	WO 2000-FR2190	20000728 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2796943	A1	20010202	FR 1999-9894	19990730 <--

PRIORITY APPLN. INFO.: FR 1999-9894 A 19990730
OTHER SOURCE(S): MARPAT 134:163045
GI



I



II

AB The invention concerns novel dihydro-8-benzoxazinecarboxamide derivs. I [R1 = alkyl, OH, alkoxy, hydroxyalkyl, (un)substituted (hetero)aryl; R2 = H, CO2H or derived radicals; R3 = H, (un)substituted alkyl; R4, R5 = H, alkyl; R6, R7 = H; or R6R7 = O; R8 = H, halo; R9 = H, halo, alkyl, (un)substituted (hetero)aryl, cycloalkyl, etc.; R10 = H, alkyl, alkoxy; X = (CH2)0-3; Y, Z = alkylene; Het = imidazole or pyridine nucleus; Ar = benzene nucleus] and their stereoisomers and salts. The compds. are

inhibitors of farnesyltransferase, and are useful against proliferative diseases, particularly in the treatment of cancer. The invention also concerns their prepn. and their use as therapeutic agents. For instance, Me 3-aminosalicylate underwent reductive alkylation with 1-(4-chlorobenzyl)-1H-imidazole-5-carboxaldehyde, followed by cyclization of the hydroxy amine with BrCH2CH2Br to form the benzoxazine ring. The ester function was hydrolyzed, the resultant acid then amidated with Me (L)-4-chlorophenylalaninate hydrochloride, and the reintroduced ester subjected to ammonolysis, to give title compd. II, isolated as the oxalate. Compds. I inhibited growth of human colon carcinoma cells HCT116 in vitro, with IC50 values ranging from 0.1 nM to 100 .mu.M.

IT **325160-94-9P**, N-[1-(S)-Carbamoyl-2-(4-methoxyphenyl)ethyl]-4-[[3-(4-chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide **325162-05-8P**, N-[1-(S)-Carbamoyl-2-(4-methoxyphenyl)ethyl]-4-[[3-(4-chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide oxalate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of benzoxazinecarboxamide derivs. as inhibitors of farnesyltransferase for the treatment of cancer)

IT **325162-21-8P**, N-[1-(S)-Methoxycarbonyl-2-(4-methoxyphenyl)ethyl]-4-[[3-(4-chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide **325162-23-0P**, 4-[[3-(4-Chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxylic acid sodium salt **325162-26-3P**, 4-[[3-(4-Chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxylic acid methyl ester **325162-28-5P**, 3-[[[3-(4-Chlorobenzyl)-4-pyridyl]methyl]amino]salicylic acid methyl ester **325162-30-9P**, 3-[[[3-(4-Chlorobenzyl)-4-pyridyl]methylene]amino]salicylic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of benzoxazinecarboxamide derivs. as inhibitors of farnesyltransferase for the treatment of cancer)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 12 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:814464 HCAPLUS
DOCUMENT NUMBER: 133:362712
TITLE: Preparation of quinoline derivatives as inhibitors of MEK enzymes
INVENTOR(S): Boyle, Francis Thomas; Gibson, Keith Hopkinson; Poyser, Jeffrey Philip; Turner, Paul
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2000068201	A1	20001116	WO 2000-GB1697	20000503	<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1178967	A1	20020213	EP 2000-927491	20000503	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200103186	T2	20020422	TR 2001-20010318	20000503	<--
BR 2000010391	A	20020702	BR 2000-10391	20000503	<--
EE 200100589	A	20030217	EE 2001-589	20000503	
NZ 514980	A	20031031	NZ 2000-514980	20000503	
ZA 2001008971	A	20030130	ZA 2001-8971	20011030	
BG 106073	A	20020531	BG 2001-106073	20011101	<--
NO 2001005448	A	20020107	NO 2001-5448	20011107	<--

PRIORITY APPLN. INFO.: GB 1999-10577 A 19990508
WO 2000-GB1697 W 20000503

OTHER SOURCE(S): MARPAT 133:362712
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; or a pharmaceutically acceptable salt thereof wherein: n is 0-1; X and Y are independently selected from NH, O, S, or NR8 where R8 is alkyl of 1-6 carbon atoms and X may addnl. comprise a CH2 group; R7 is a group (CH2)mR9 where m is 0, or an integer of from 1-3 and R9 is a substituted aryl group, an optionally substituted cycloalkyl ring of up to 10 carbon atoms, or an optionally substituted heterocyclic ring or an N-oxide of any nitrogen contg. ring; R6 is a divalent cycloalkyl of 3 to 7 carbon atoms, which may be optionally further substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a divalent pyridinyl, pyrimidinyl, or Ph ring; wherein the pyridinyl, pyrimidinyl, or Ph ring may be optionally further substituted with one or more specified groups; R1, R2, R3 and R4 are each independently selected from hydrogen or various specified org. groups]. Title compds. are useful as pharmaceuticals for the inhibition of MEK activity. Thus, the title compd. II was prepd. and tested in HT29 human colon tumor cell proliferation assay.

IT **306999-01-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of quinoline derivs. as inhibitors of MEK enzymes)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 13 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:725622 HCAPLUS
DOCUMENT NUMBER: 133:296442
TITLE: Preparation of neurotrophic thio substituted pyrimidines
INVENTOR(S): Kelley, James L.; Krenitsky, Thomas A.; Beauchamp, Lilia M.
PATENT ASSIGNEE(S): Krenitsky Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2000059893	A1	20001012	WO 2000-US9004	20000405	<--

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1165522 A1 20020102 EP 2000-921705 20000405 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1999-127923P P 19990406
US 1999-128842P P 19990412
WO 2000-US9004 W 20000405

OTHER SOURCE(S): MARPAT 133:296442
GI



I

AB The title compds. [I; R1 = NHR4 (R4 = aryl, alkyl, etc.), (un)substituted piperazino, homopiperazino, etc.; R2 = H, NH2; R3 = H; X = substituted aryl] and their pharmaceutically acceptable salts, useful in therapy, particularly in the treatment of neurodegenerative or other neurol. disorders of the central and peripheral systems, were prepd. and formulated. E.g., a multi-step synthesis of I [R1 = trans-4-hydroxycyclohexylamino; R2 = NH2; R3 = H; X = 4-ClC6H4] which doubled the ChAT activity over the activity with NGF alone at 0.04 .mu.M, was given.

IT **300855-81-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of neurotrophic thio substituted pyrimidines)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 14 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:725485 HCAPLUS
DOCUMENT NUMBER: 133:296658
TITLE: Preparation of desleucyl glycopeptide antibiotics
INVENTOR(S): Kahne, Daniel; Walker, Suzanne; Silva, Domingos J.
PATENT ASSIGNEE(S): The Trustees of Princeton University, USA; Incara Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059528	A1	20001012	WO 2000-US8559	20000331 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,

SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1173193 A1 20020123 EP 2000-919942 20000331 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

US 6518243 B1 20030211 US 2000-540761 20000331
PRIORITY APPLN. INFO.: US 1999-127516P P 19990402
WO 2000-US8559 W 20000331

AB Compds. that are analogs of glycopeptide antibiotics are disclosed. The compds. have the formula A1-A2-A3-A4-A5-A6-A7, where each of the groups A2 to A7 is a modified or unmodified .alpha.-amino acid residue, A1 is optional and, when present, is an org. group other than N-substituted leucine, and at least one of the groups A1 to A7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, where at least one of said sugar residues is modified to bear at least one hydrophobic substituent. Methods of making these compds., compns. including these compds., and methods of using the compds. to treat infections in a host are also disclosed. Antibacterial test data are tabulated for > 350 compds. of the invention.

IT **300581-67-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of desleucyl glycopeptide antibiotics)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 15 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:619066 HCAPLUS
DOCUMENT NUMBER: 134:424
TITLE: Design, synthesis and biological evaluation of pyridine-phenylpiperazines: A novel series of potent and selective .alpha.1a-adrenergic receptor antagonist
AUTHOR(S): Kuo, G.-H.; Prouty, C.; Murray, W. V.; Pulito, V.; Jolliffe, L.; Cheung, P.; Varga, S.; Evangelisto, M.; Shaw, C.
CORPORATE SOURCE: Drug Discovery Division, The R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, 08869, USA
SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(9), 2263-2275
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:424
GI



I

AB Beginning from the screening hit and literature .alpha.1-adrenergic compds., a hybridized basic skeleton A was proposed as the pharmacophore for potent and selective .alpha.1a-AR antagonists. Introduction of a hydroxy group to increase the flexibility afforded B which served as the screening model and resulted in the identification of the second-generation lead 1. Using the Topliss approach, a no. of potent and selective .alpha.1a-AR antagonists were discovered. In all cases, binding affinity and selectivity at the .alpha.1a-AR of S-hydroxy enantiomers were higher than the R-hydroxy enantiomers. As compared to the des-hydroxy analogs, the S-hydroxy enantiomers displayed comparable potency and better selectivity at .alpha.1a-AR. The S-hydroxy enantiomer (I) (Ki=0.79 nM; =800; =104) was slightly less potent but much more selective at .alpha.1a-AR than tamsulosin (Ki=0.13 nM, =15, =1.4). I displayed higher selectivity in inhibiting rat prostate contraction over rat aorta contraction and also exhibited a higher degree of uroselectivity than tamsulosin in the anesthetized dog model.

IT **240418-34-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design, synthesis and biol. evaluation of pyridinephenylpiperazines as a novel series of potent and selective .alpha.1a-adrenergic receptor antagonist)

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 16 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:139171 HCAPLUS
DOCUMENT NUMBER: 132:180599
TITLE: Preparation of phenoxypyrazineacetic acid derivatives as agrochemical fungicides
INVENTOR(S): Kusano, Nobuyuki; Eitsuka, Takayoshi; Niizeki, Yoshitaka
PATENT ASSIGNEE(S): Kureha Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 34 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000063362	A2	20000229	JP 1998-244408	19980814 <--

PRIORITY APPLN. INFO.: JP 1998-244408 19980814
OTHER SOURCE(S): MARPAT 132:180599
GI



I

AB The title compds. I [R1 = H, alkyl; Y = alkoxy, etc.; X = H, halo, etc.; n = 0 - 5; Z = O, etc.] are prepd. The title compd. I [Xn = 3-Me; R1 = Me; Y = OMe; Z = O] at 1000 ppm gave 100% control of Puccinia recondita.

IT **259673-08-0P 259673-17-1P 259673-20-6P**
259673-23-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenoxypyrazineacetic acid derivs. as agrochem. fungicides)

L30 ANSWER 17 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:686697 HCAPLUS
DOCUMENT NUMBER: 131:299463
TITLE: Preparation of heteroarylmethylpiperazinones and related compounds as inhibitors of farnesyl-protein transferase
INVENTOR(S): Wei, Dong D.; Williams, Theresa M.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 30 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5972942	A	19991026	US 1997-827485	19970327 <--

PRIORITY APPLN. INFO.: US 1997-827485 19970327
OTHER SOURCE(S): MARPAT 131:299463
GI



I

AB Title compds. [I; Q = (R8)rVA1[C(R1a)2]nA2[C(R1a)2]n[W(R9)q]t[C(R1b)2]pX; R1a, R1b = H, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, (substituted) alkyl, etc.; R2, R3 = H, (substituted) alkyl, alkenyl, alkynyl, aryl, heterocyclyl, etc.; R2R3C = (CH2)u, etc.; R4 = H, Me; R8 = H, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, (substituted) alkyl, etc.; R9 = H, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, (substituted) alkyl, etc.; A1, A2 = bond, CH:CH2, C.tplbond.C, CO, O, imino, S, SO, SO2, etc.; E = (CH2)s; G = H2, O; V = H, heterocyclyl, aryl, alkyl, alkenyl, etc.; W = heterocyclyl; X = CH2, CO, S, SO, SO2; Z = (substituted) alkyl, cycloalkyl; n, p = 0-4; q = 1, 2; r = 0-5; s, t = 0, 1; with provisos], were prepd. Thus, 1-tert-butoxycarbonyl-2(S)-n-butyl-4-(2,2,2-trifluoroethyl)piperazin-5-one was stirred 1 h with CF3CO2H in CH2Cl2 to give a residue which was dissolved in dichloroethane and treated with N-methylmorpholine, Na(AcO)3BH, and 1-(4-cyanobenzyl)imidazolyl-5-carboxaldehyde followed by stirring overnight to give 2(S)-n-butyl-1-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-4-(2,2,2-trifluoroethyl)piperazin-5-one dihydrochloride. I inhibited human FPTase with IC50.ltoreq.50 .mu.M.

IT **198084-17-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroarylmethylpiperazinones and related compds. as inhibitors of farnesyl-protein transferase)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 18 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:549258 HCAPLUS
DOCUMENT NUMBER: 131:184970
TITLE: Preparation of N-pyridinylcarbonylaminoalkyl-N'-arylpiperazines for treatment of benign prostatic hyperplasia.
INVENTOR(S): Kuo, Gee-Hong; Murray, William V.; Prouty, Catherine P.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9942448	A1	19990826	WO 1999-US3608	19990219	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
ZA 9901315	A	20001120	ZA 1999-1315	19990218	<--
US 6218396	B1	20010417	US 1999-252313	19990218	<--
AU 9933025	A1	19990906	AU 1999-33025	19990219	<--
AU 766398	B2	20031016			
BR 9909647	A	20001121	BR 1999-9647	19990219	<--
EP 1054868	A1	20001129	EP 1999-934281	19990219	<--
EP 1054868	B1	20030924			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO					
TR 200003220	T2	20010420	TR 2000-20000322	19990219	<--
JP 2002503724	T2	20020205	JP 2000-532400	19990219	<--
NZ 506462	A	20030725	NZ 1999-506462	19990219	
CN 1121390	B	20030917	CN 1999-803027	19990219	
AT 250580	E	20031015	AT 1999-934281	19990219	
PT 1054868	T	20040130	PT 1999-934281	19990219	
NO 2000004141	A	20001019	NO 2000-4141	20000818	<--
HK 1030776	A1	20040130	HK 2001-101679	20010308	

PRIORITY APPLN. INFO.: US 1998-75321P P 19980220
WO 1999-US3608 W 19990219

OTHER SOURCE(S): MARPAT 131:184970
GI



I



II

AB Title compds. [I; R1 = H, halo, alkoxy, OH, alkyl; R2 = (substituted) alkyl, Ph, phenylalkyl; R3 = H, OH, alkoxy, O; R4 = H, alkyl, (substituted) phenylalkyl; R5 = (substituted) alkyl, Ph, phenylalkyl; X = O, S, NH; dotted line = optional double bond], were prepd. Thus, 1-(2-isopropoxyphenyl)piperazine was heated with 1-azido-3-tosyloxypropan-2-ol at 100.degree. for 36 h to give 76% 1-(2-isopropoxyphenyl)-4-(3-azido-2-hydroxypropyl)piperazine. The latter was hydrogenated in MeOH/aq. HCl over Pd/C at 50 psi for 16 h to give 95% amine, which was stirred with 2-phenoxypyridine-3-carbonyl chloride, DMAP, and diisopropylethylamine in CH2Cl2 to give 69% title compd. (II). II inhibited norepinephrine-induced contractile response in aortic tissue and prostate tissue with IC50 = 4.74 .mu.M and 0.143 .mu.M, resp.

IT **240418-34-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-pyridinylcarbonylaminoalkyl-N'-arylpiperazines for treatment of benign prostatic hyperplasia)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 19 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:487274 HCAPLUS
DOCUMENT NUMBER: 131:116520
TITLE: Preparation of phenylalanine derivatives as pharmaceutical agents
INVENTOR(S): Head, John Clifford; Archibald, Sarah Catherine; Warrellow, Graham John; Porter, John Robert
PATENT ASSIGNEE(S): Celltech Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937618	A1	19990729	WO 1999-GB279	19990127 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6329372	B1	20011211	US 1999-237060	19990126 <--
AU 9924320	A1	19990809	AU 1999-24320	19990127 <--
EP 1051399	A1	20001115	EP 1999-903798	19990127 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002501051	T2	20020115	JP 2000-528542	19990127 <--
US 2002035127	A1	20020321	US 2001-964161	20010926 <--

PRIORITY APPLN. INFO.:

GB 1998-1674	A	19980127
GB 1998-26669	A	19981203
US 1999-237060	A1	19990126
WO 1999-GB279	W	19990127

OTHER SOURCE(S): MARPAT 131:116520

AB Phenylalanine derivs. 4-[R1(Alk1)rL1s]C6H2RaRb(Alk2)mCHRR2NR3COHet [R is a carboxylic acid or deriv.; R1 = H, OH, alkoxy or optionally substituted cycloaliph., polycycloaliph., heterocycloaliph., polyheterocycloaliph., arom, or heteroarom. group; Alk1 = optionally substituted aliph. or heteroaliph. chain; L1 is a linker atom or group; r, s = 0, 1; Ra, Rb = -L2(CH2)pL3Rcq, where L2, L3 = a covalent bond or linker atom or group; p = 0, 1; q = 1-3; Rc = H, halo, alkyl, OH, alkoxy, etc.; Alk2 = alkylene; m = 0, 1; R2 = H, Me; R3 = H, alkyl; Het is an optionally substituted heteroarom. group] and their salts, solvates, hydrates and N-oxides were prepd. as pharmaceutical agents. Thus, N-(2-chloronicotinoyl)-N'-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine was prepd. by coupling reaction of N-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine Me ester with 2-chloronicotinoyl chloride followed by ester hydrolysis. Title compds. were tested for inhibition of integrin-dependent cell adhesion and generally have IC50 values in the .alpha.4.beta.1 and .alpha.4.beta.7 assays of 1.mu.M and below.

IT **232617-65-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylalanine derivs. as pharmaceutical agents)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 20 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1999:404941 HCAPLUS
DOCUMENT NUMBER:	131:44844
TITLE:	preparation of novel pyrimidine-5-carboxamide derivatives as tyrosinase inhibitors
INVENTOR(S):	Hisamichi, Hiroyuki; Naito, Ryo; Kawazoe, Souichirou; Toyoshima, Akira; Tanabe, Kazuhito; Nakai, Eiichi; Ichikawa, Atsushi; Orita, Akiko; Takeuchi, Makoto
PATENT ASSIGNEE(S):	Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE:	PCT Int. Appl., 43 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931073	A1	19990624	WO 1998-JP5643	19981214 <--

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9915071	A1	19990705	AU 1999-15071	19981214	<--
EP 1054004	A1	20001122	EP 1998-959197	19981214	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
US 6432963	B1	20020813	US 2000-581595	20000615	<--

PRIORITY APPLN. INFO.: JP 1997-344588 A 19971215
WO 1998-JP5643 W 19981214

OTHER SOURCE(S): MARPAT 131:44844

GI



I

AB Pyrimidine-5-carboxyamide derivs. or salts [I; X = O, S, NR1, CO, NR1CO, CONR1, C=NOR1, a bond; Y = lower alkylene optionally substituted by OR1 or NHR1, a bond; Z = O, NR2, a bond; A = H, optionally substituted lower alkyl, lower alkyl optionally having CO, optionally substituted aryl or heteroaryl, optionally substituted cycloalkyl, optionally substituted and satd. N heterocycle; B = optionally substituted aryl or heteroaryl; R1, R2 = H or lower alkyl optionally contg. CO], effective tyrosinase inhibitors useful as 5-HT antagonists, antiallergics, were prepd. I showed IC50 < 0.1 .mu.M in scintillation proximity assay. I were effective at 0.1-10 mg/kg-day p.o.

IT **227449-77-6P 227449-85-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel pyrimidine-5-carboxamide derivs. as tyrosinase inhibitors)

IT **227449-54-9P 227449-65-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of novel pyrimidine-5-carboxamide derivs. as tyrosinase inhibitors)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 21 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:404931 HCAPLUS
DOCUMENT NUMBER: 131:58848
TITLE: Preparation of pyridine derivatives as 5-HT7 receptor binding agents
INVENTOR(S): Adachi, Makoto; Sasatani, Takashi; Chomei, Nobuo; Fukui, Yoshikazu; Yasui, Mitsuru
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931062	A1	19990624	WO 1998-JP5561	19981209 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9915045	A1	19990705	AU 1999-15045	19981209 <--
PRIORITY APPLN. INFO.:			JP 1997-347574	19971217
			WO 1998-JP5561	19981209

OTHER SOURCE(S): MARPAT 131:58848
GI



I



II

AB The title compds. I [Ar represents optionally substituted aryl or optionally substituted heteroaryl; R1 represents hydrogen, halogeno, alkyl, alkenyl, alkyloxy, etc.; R2 and R3 independently represent each hydrogen or optionally substituted alkyl or R2 and R3 may form together with the adjacent nitrogen atom an optionally substituted heterocycle; and n is an integer of 1 to 6] are prepd. In an in vitro test for 5-HT7 receptor binding, piperazinylmethylpyridine deriv. II showed the Ki value of 57 nM.

IT **228095-91-8P 228095-92-9P 228095-95-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridine derivs. as 5-HT7 receptor binding agents)

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 22 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1999:388161 HCAPLUS
DOCUMENT NUMBER:	131:58652
TITLE:	Preparation of N-adamantylmethylbenzamides and analogs as purinergic P2Z receptor antagonists
INVENTOR(S):	Baxter, Andrew; Mcinally, Thomas; Mortimore, Michael; Cladingboel, David
PATENT ASSIGNEE(S):	Astra Pharmaceuticals Ltd., UK; Astra Aktiebolag
SOURCE:	PCT Int. Appl., 86 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9929661	A1	19990617	WO 1998-SE2188	19981201	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2312420	AA	19990617	CA 1998-2312420	19981201	<--
AU 9917913	A1	19990628	AU 1999-17913	19981201	<--
AU 744280	B2	20020221			
EP 1036059	A1	20000920	EP 1998-962751	19981201	<--
EP 1036059	B1	20020918			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 9813390	A	20001003	BR 1998-13390	19981201	<--
TR 200001605	T2	20001023	TR 2000-20000160519981201		<--
JP 2001525392	T2	20011211	JP 2000-524258	19981201	<--
EE 200000378	A	20011217	EE 2000-20000037819981201		<--
AT 224360	E	20021015	AT 1998-962751	19981201	
PT 1036059	T	20030228	PT 1998-962751	19981201	
ES 2184352	T3	20030401	ES 1998-962751	19981201	
RU 2214997	C2	20031027	RU 2000-117574	19981201	
US 6201024	B1	20010313	US 1999-230478	19990126	<--
NO 2000002786	A	20000731	NO 2000-2786	20000531	<--
US 2001003121	A1	20010607	US 2000-745740	20001226	<--
US 6303659	B2	20011016			
US 6258838	B1	20010710	US 2000-745346	20001226	<--

PRIORITY APPLN. INFO.:

SE 1997-4544	A	19971205
WO 1998-2188	W	19981201
WO 1998-SE2188	W	19981201
US 1999-230478	A1	19990126

OTHER SOURCE(S): MARPAT 131:58652

GI



I

AB Title compds. [I; R1 = (CH2)xNHCOR; R = (un)substituted Ph, -pyridyl, -indolyl, etc.; R2 = H or halo; Z = O or CH2; X = 1 or 2] were prepd. Thus, 1-adamantanemethylamine was amidated by 2,4-Cl2C6H3COCl to give I (R1 = CH2NHCOC6H3Cl2-2,4, R2 = H, Z = CH2). Data for biol. activity of I were given.

IT **227327-50-6P 227327-73-3P 227327-80-2P**
227327-82-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-adamantylmethylbenzamides and analogs as purinergic P2Z

receptor antagonists)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 23 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:325908 HCAPLUS
DOCUMENT NUMBER: 130:352186
TITLE: Substituted pyridine compounds as anti-inflammatory agents
INVENTOR(S): Mantlo, Nathan B.; Schlachter, Steven T.; Josey, John A.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 254 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9924404	A1	19990520	WO 1998-US23510	19981104	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 6022884	A	20000208	US 1998-185119	19981103	<--
CA 2307552	AA	19990520	CA 1998-2307552	19981104	<--
AU 9913065	A1	19990531	AU 1999-13065	19981104	<--
AU 742442	B2	20020103			
EP 1028945	A1	20000823	EP 1998-956570	19981104	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2001522834	T2	20011120	JP 2000-520418	19981104	<--
US 6184237	B1	20010206	US 1999-431410	19991101	<--
US 6333341	B1	20011225	US 2000-642860	20000821	<--
US 2002035094	A1	20020321	US 2001-932281	20010817	<--
US 6458813	B2	20021001			

PRIORITY APPLN. INFO.:	US 1997-64953P	P	19971107
	US 1998-185119	A	19981103
	WO 1998-US23510	W	19981104
	US 1999-431410	A3	19991101
	US 2000-642860	A3	20000821

OTHER SOURCE(S): CASREACT 130:352186; MARPAT 130:352186
GI



I



II

AB Title compds. [I; wherein X is O, S, S(O), S(O)2 or NR2; Y is -C(O)-NR3R4 or -NR4-C(O)-R3; R1 is a cycloalkyl, aryl, heterocyclyl or heteroaryl radical which is optionally substituted by 1-4 radicals of alkyl, halo, haloalkyl, cyano, azido, nitro, amidino, R18-Z18- or R18-Z18-alkyl; provided that the total no. of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R1 is 1-3; and provided when Y is -NR4-C(O)-R3 and X is O or S, R1 is other than a 2-pyrimidinyl radical; R2 is a hydrogen or alkyl radical; R3 is an aryl or heteroaryl radical which is optionally substituted by 1-5 radicals of alkyl, halo, haloalkyl, cyano, azido, nitro, amidino, R19-Z19- or R19-Z19-alkyl; provided that the total no. of aryl and heteroaryl radicals in R3 is 1-3; and provided when Y is -C(O)- NR3R4, R3 is other than a Ph or naphthyl having an amino, nitro, cyano, carboxy or alkoxycarbonyl] or a pharmaceutically acceptable salt thereof, are prepd. and effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes or a pharmaceutically acceptable salt thereof.

IT **224798-42-9P 224799-37-5P 224800-84-4P**
224801-77-8P 224802-65-7P 224803-75-2P
224804-80-2P 224805-72-5P 224806-63-7P
224807-56-1P 224808-46-2P 224809-64-7P
224810-57-5P 224811-52-3P 224812-92-4P
224813-98-3P 224814-98-6P 224822-03-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted pyridines as anti-inflammatory agents)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 24 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:205309 HCAPLUS
DOCUMENT NUMBER: 130:237591
TITLE: Preparation of piperazinones as inhibitors of farnesyl-protein transferase
INVENTOR(S): Dinsmore, Christopher J.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 28 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5885995	A	19990323	US 1997-827482	19970327 <--

PRIORITY APPLN. INFO.: US 1997-827482 19970327
OTHER SOURCE(S): MARPAT 130:237591
GI



AB The title compds. I [R1a, R1b = H, aryl, cycloalkyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; CH2 = H, Me; R8 = H, aryl, perfluoroalkyl, etc.; R9 = H, alkenyl, alkynyl, F, Cl, etc.; A1, A2 = bond, CH:CH, C.tplbond.C, etc.; V = H, aryl, alkyl, alkenyl; W = pyridinyl, imidazolyl; Z = aryl, arylmethyl, arylsulfonyl, etc.; m = 1; n = 0-4; p = 1; q = 1, 2; p' = 0-4; n' = 0], which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras, were prepd. E.g., 4-(3-chlorophenyl)-1-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone hydrochloride was prepd.

IT **197853-30-8P 197853-33-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinones as inhibitors of farnesyl-protein transferase)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 25 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:77533 HCAPLUS
DOCUMENT NUMBER: 130:153469
TITLE: Novel polyamine analogs as therapeutic and diagnostic agents
INVENTOR(S): Vermeulin, Nicolaas M. J.; O'Day, Christine L.; Webb, Heather K.; Burns, Mark R.; Bergstrom, Donald E.
PATENT ASSIGNEE(S): Oridigm Corporation, USA
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903823	A2	19990128	WO 1998-US14896	19980715 <--
WO 9903823	A3	19990408		

W: AL, AM, AU, AZ, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9884968	A1	19990210	AU 1998-84968	19980715 <--
AU 758570	B2	20030327		
EP 1001927	A2	20000524	EP 1998-935790	19980715 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001510181	T2	20010731	JP 2000-503054	19980715 <--
US 6172261	B1	20010109	US 1999-341400	19990903 <--
US 6646149	B1	20031111	US 2000-584175	20000531

PRIORITY APPLN. INFO.:	US 1997-52586P	P	19970715
	US 1997-65728P	P	19971114
	US 1998-85538P	P	19980515
	WO 1998-US14896	W	19980715
	US 1999-341400	A2	19990903
	US 1999-396523	A2	19990915

OTHER SOURCE(S): MARPAT 130:153469

GI



I

AB Title inhibitors RXR1 [R =H, or is a head group consisting of a straight or branched C1-10 aliph., alicyclic, single or multiring arom., single or multiring aryl substituted aliph., etc.; R1 is a polyamine; X = CO, NHCO, NHCS, SO2] and pharmaceutical acceptable salts of polyamine transport having inhibition consts. two orders of magnitude lower than those of known compds. are disclosed. These polyamine analogs are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury and the introduction of a 3-amidopropyl group to the diaminobutyl part of spermidine produce a significantly better transport inhibitor. Novel chem. synthetic methods to obtain polyamine analogs are disclosed, including the prodn. of a combinatorial polyamine library. These approaches yield analogs with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system. Thus, I was prepd. from 1-aminoanthracene, 4-nitrophenyl chloroformate, and spermine.

IT **220221-36-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of polyamines as therapeutic and diagnostic agents)

L30 ANSWER 26 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1999:45145 HCAPLUS
DOCUMENT NUMBER:	130:125091
TITLE:	Preparation of piperazine-2,3-dione derivatives as inhibitors of farnesyl-protein transferase
INVENTOR(S):	Dinsmore, Christopher J.; Williams, Theresa M.
PATENT ASSIGNEE(S):	Merck and Co., Inc., USA
SOURCE:	U.S., 29 pp. CODEN: USXXAM
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5859012	A	19990112	US 1997-823923	19970325 <--

PRIORITY APPLN. INFO.: US 1997-823923 19970325
OTHER SOURCE(S): MARPAT 130:125091
GI



I



II

AB The invention is directed to piperazine-2,3-dione compds. I [A1, A2 = bond, CH:CH, C.tplbond.C, CO, (un)substituted CONH, NHCO, O, NH, S, S(O), SO2, etc.; R, R1 = H, aryl, cycloalkyl, alkenyl, alkynyl, cyano, NO2, N3, (un)substituted OH, (un)substituted NH2, (un)substituted alkyl, etc.; R2, R3 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted aryl, (un)substituted carbamoyl, (un)substituted CO2H; R8 = H, aryl, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, (un)substituted OH, (un)substituted CONH2, cyano, NO2, N3, (un)substituted alkyl, etc.; R9 = H, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, (un)substituted OH, (un)substituted CONH2, cyano, NO2, N3, (un)substituted NH2, (un)substituted alkyl, etc.; V = H, aryl, alkenyl, alkyl with 0-4 C atoms replaced by O, S, or N; W = imidazole; X = bond, CH2, CO, S, SO, SO2; Z = (un)substituted aryl, arylmethyl, (un)substituted arylsulfonyl, (un)substituted alkyl, or (un)substituted cycloalkyl, etc.; n, p = 0-4; q = 1, 2; p1 = 0-5, provided that p1 = 0 when V = H; p2 = 1], which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compns. contg. the invention compds., and methods for inhibiting FPTase and the farnesylation of the oncogene protein Ras. The compds. have application as antitumor agents, and are also useful or potentially useful for treating other proliferative diseases, viral infections, restenosis, polycystic kidney disease, and fungal infections. Thus, 1-(4-cyanobenzyl)-5-imidazolecarboxaldehyde was added to a mixt. of NaBH(OAc)3, Me N-(2-aminoethyl)-N-(3-chlorophenyl)oxalamide hydrochloride, and 4.ANG. mol. sieves at 0.degree., and the mixt. was stirred at room temp. overnight to give, after salt formation with HCl, the title compd. II.HCl. Several title compds., including II, inhibited human FPTase in vitro with IC50 of .ltoreq. 10 .mu.M.

IT **219919-15-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of piperazinedione derivs. as inhibitors of farnesyl protein transferase)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 27 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:34471 HCAPLUS
DOCUMENT NUMBER: 130:95565
TITLE: Preparation of 1-aryl(carbonyl)-2-piperazinones and analogs as farnesyl protein transferase inhibitors
INVENTOR(S): Anthony, Neville J.; Ciccarone, Terrence M.; Dinsmore, Christopher J.; Gomez, Robert P.; Williams, Theresa M.; Hartman, George D.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 68 pp., Cont.-in-part of U.S. Ser. No. 470,690, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5856326	A	19990105	US 1996-600728	19960301 <--
CA 2216707	AA	19961003	CA 1996-2216707	19960325 <--
WO 9630343	A1	19961003	WO 1996-US4019	19960325 <--
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, US, US, UZ, VN, AM, AZ, BY, KG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9653223	A1	19961016	AU 1996-53223	19960325 <--
AU 710672	B2	19990923		
EP 820445	A1	19980128	EP 1996-909851	19960325 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
BR 9607953	A	19980714	BR 1996-7953	19960325 <--
CN 1195340	A	19981007	CN 1996-194206	19960325 <--
JP 10511098	T2	19981027	JP 1996-529559	19960325 <--
JP 3043815	B2	20000522		
ZA 9602433	A	19961002	ZA 1996-2433	19960327 <--
NO 9704457	A	19971128	NO 1997-4457	19970926 <--

PRIORITY APPLN. INFO.:
US 1995-412829 B2 19950329
US 1995-470690 B2 19950606
US 1996-600728 A 19960301
WO 1996-US4019 W 19960325

OTHER SOURCE(S): MARPAT 130:95565
GI



II

AB R1A1Z1A2Z2Z3Z4XZR [I; A1,A2 = bond, O, CO, CH:CH, etc.; R = (un)substituted heterocyclylcarbonyl or -arylcarbonyl when Z = e.g.,

(un)substituted 1,4-piperazinediyl; R = (un)substituted (hetero)aryl(methyl) or -(sulfonyl) when Z = e.g., (un)substituted 3-oxopiperazine-1,4-diyl; R1 = H, alkyl, aryl, etc.; X = CH2, CO, SO0-2; Z1,Z2,Z4 = bond or (un)substituted alkylene; Z3 = bond or (un)substituted heterocyclylene] were prepd. Thus, (S)-BuCH(NHCO2CMe3)CO2H was amidated by MeONHMe and the reduced product reductively aminated by 2,3-Me2C6H3NH2 to give, after cyclocondensation with ClCH2COCl, arylpiperazininone (S)-II (III; R1 = H) which was deprotected and the product reductively condensed with 1-triphenylmethylimidazole-4-carboxaldehyde to give, after deprotection, III (R1 = 4-imidazolylmethyl). Data for biol. activity of I were given.

IT **219552-94-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-aryl(carbonyl)-2-piperazinones and analogs as farnesyl protein transferase inhibitors)

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 28 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:479031 HCAPLUS
DOCUMENT NUMBER: 129:122662
TITLE: Preparation of imidazole derivatives as inhibitors of farnesyl-protein transferase
INVENTOR(S): Bergman, Jeffrey; Dinsmore, Christopher
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 21 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5780488	A	19980714	US 1997-824588	19970326 <--
PRIORITY APPLN. INFO.:			US 1997-824588	19970326

OTHER SOURCE(S): MARPAT 129:122662

AB The title compds. (R6)rVA1(CR1a2)nA2(C1b2)n(WR7)t(CR22)pA3(CR22)pXR3R4 [R1a, R1b, R2 = H, aryl, heterocyclyl, etc.; R3, R4 = H, F, Cl, etc.; A3 = NR5S(O)m, etc.; m = 0 - 2; R5 = H, (un)substituted aryl, etc.; R6, R7 = H, aryl, heterocyclyl, etc.; A1, A2 = bond, CH:CH, etc.; X = aryl, heteroaryl; V = H, heterocyclyl, etc.; W = heterocyclyl; n, p = 0 - 4; r = 0 - 5, provided that r is 0 when V is hydrogen, and t is 1], useful as farnesyl-protein transferase inhibitors (no data), are prepd. The present invention is directed to compds. which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compns. contg. the compds. of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

IT **197786-21-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazole derivs. as inhibitors of farnesyl-protein transferase)

IT **197786-45-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of imidazole derivs. as inhibitors of farnesyl-protein transferase)

IT **197786-28-0 197786-35-9**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of imidazole derivs. as inhibitors of farnesyl-protein transferase)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 29 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:115356 HCAPLUS
DOCUMENT NUMBER: 128:154011
TITLE: Preparation of 9-thioxanthenecarboxamides and 9-fluorenecarboxamides as inhibitors of microsomal triglyceride transfer protein
INVENTOR(S): Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; Sulsky, Richard B.; Tino, Joseph A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S., 98 pp., Cont.-in-part of U. S. Ser. No.472,067.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5712279	A	19980127	US 1996-548811	19960111 <--
CA 2091102	AA	19930907	CA 1993-2091102	19930305 <--
HU 67962	A2	19950529	HU 1993-627	19930305 <--
HU 218419	B	20000828		
JP 06038761	A2	19940215	JP 1993-46499	19930308 <--
EP 584446	A2	19940302	EP 1993-103697	19930308 <--
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	AT 1993-103697	19930308 <--
PT 584446	T	20020930	PT 1993-103697	19930308
ES 2178640	T3	20030101	ES 1993-103697	19930308
AU 670930	B2	19960808	AU 1993-34064	19930309 <--
AU 9334064	A1	19930909		
US 5739135	A	19980414	US 1995-472067	19950606 <--
ZA 9601340	A	19970911	ZA 1996-1340	19960220 <--
LT 4367	B	19980825	LT 1997-152	19970919 <--

PRIORITY APPLN. INFO.:
US 1995-391901 B2 19950221
US 1995-472067 A2 19950606
US 1992-847503 A 19920306
US 1993-117362 A2 19930903
US 1994-284808 B2 19940805

OTHER SOURCE(S): MARPAT 128:154011
GI



I



II



III

AB The title compds. [I; Z = a bond, S; X1, X2 = H, halo; x = 2-6; (CH2)x is optionally substituted with 1-3 substituents such as alkyl or halo; R5 = (un)substituted heteroaryl, aryl, heterocycloalkyl, cycloalkyl] and their piperidine N-oxides, which inhibit microsomal triglyceride transfer protein and thus are useful for preventing or treating atherosclerosis, pancreatitis secondary to hypertriglyceridemia, hyperglycemia, or obesity, and for lowering serum lipid levels, or preventing and/or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, and/or hypertriglyceridemia, were prepd. Thus, reaction of 9-fluorenecarboxamide II (prepn. of both reagents is described) with piperidine III in PhMe/DMF afforded the title compd. I [Z = a bond; X1 = X2 = H; (CH2)x = (CH2)2CF2CH2; R5 = 2-biphenyl]. Compds. I are effective at 5-500 mg/day.

IT **182432-31-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 9-thioxanthenecarboxamides and 9-fluorenecarboxamides as inhibitors of microsomal triglyceride transfer protein)

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 30 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:679076 HCAPLUS
DOCUMENT NUMBER: 127:331505
TITLE: Preparation of 1-imidazolylmethyl-4-phenylpiperazine-2,3-diones and analogs as farnesyl protein transferase inhibitors
INVENTOR(S): Dinsmore, Christopher J.; Williams, Theresa M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Dinsmore, Christopher J.; Williams, Theresa M.
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736889	A1	19971009	WO 1997-US5058	19970327 <--

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU,

IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX,
NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN,
YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, NE, SN, TD, TG

CA 2250190	AA	19971009	CA 1997-2250190	19970327	<--
AU 9725930	A1	19971022	AU 1997-25930	19970327	<--
AU 716338	B2	20000224			
EP 891350	A1	19990120	EP 1997-917667	19970327	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
JP 2000507580	T2	20000620	JP 1997-535440	19970327	<--

PRIORITY APPLN. INFO.:
US 1996-14589P P 19960403
GB 1996-14315 A 19960708
WO 1997-US5058 W 19970327

OTHER SOURCE(S): MARPAT 127:331505
GI



II

AB R1A1[C(R1a)2]nA2[C(R1a)2]nZ[C(R1b)2]pZ1Z2R [I; A1,A2 = bond, CH:CH, CO, O, CONH, etc.; R = (un)substituted (cyclo)alkyl, -(hetero)aryl(methyl), -(hetero)arylsulfonyl; R1 = H, (un)substituted heterocyclyl, -aryl, -alk(en)yl; R1a,R1b = H, alkyl, acyl, heterocyclyl, aryl, etc.; Z = bond or (un)substituted heterocyclylene; Z1 = bond, CH2, CO, SO0-2; Z2 = (un)substituted 2,3-dioxopiperazine-1,4-diyl; n,p = 0-4] were prepd. Thus, 1-trityl-4-acetoxymethylimidazole (prepn. given) was condensed with BrCH2C6H4(CN)-4 and the deprotected product oxidized to give 1-(4-cyanobenzyl)imidazole-5-carboxaldehyde which was cyclocondensed with 3-ClC6H4N(COCO2Me)CH2CH2NH2.HCl (prepn. given) to give title compd. II.HCl. Data for biol. activity of I were given.

IT **197912-97-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-imidazolylmethyl-4-phenylpiperazine-2,3-diones and analogs as farnesyl protein transferase inhibitors)

L30 ANSWER 31 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1997:679075 HCAPLUS
DOCUMENT NUMBER:	127:331509
TITLE:	preparation of piperazine-2,5-dione derivs. as inhibitors of farnesyl-protein transferase
INVENTOR(S):	Dinsmore, Christopher J.; Williams, Theresa M.; Bergman, Jeffrey
PATENT ASSIGNEE(S):	Merck & Co., Inc., USA; Dinsmore, Christopher J.; Williams, Theresa M.; Bergman, Jeffrey
SOURCE:	PCT Int. Appl., 96 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9736888	A1	19971009	WO 1997-US4711	19970327	<--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
US 5919785	A	19990706	US 1997-823921	19970325	<--
CA 2249604	AA	19971009	CA 1997-2249604	19970327	<--
AU 9725875	A1	19971022	AU 1997-25875	19970327	<--
AU 715667	B2	20000210			
EP 891349	A1	19990120	EP 1997-917599	19970327	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
JP 2000507576	T2	20000620	JP 1997-535347	19970327	<--

PRIORITY APPLN. INFO.: US 1996-14587P P 19960403
GB 1996-13461 A 19960627
WO 1997-US4711 W 19970327

OTHER SOURCE(S): MARPAT 127:331509

GI



I

AB The invention relates to substituted piperazine-2,5-diones I (R1a = H, C1-C6 alkyl; R1b = H, aryl, heterocycle, etc.; R2 = H, aryl, etc.; R3 = H, CH3, etc.; R4 = H, aryl, etc.; R8 = H, aryl, heterocycle, CN, NO2, etc.; A1 = CO, CH:CH, O, etc.; A2 = CO, CH:CH, O, etc.; V = H, aryl, alkyl, etc.; W = heterocycle; X = CH2, CO, bond, etc.; Z = Aryl, arylmethyl, arylsulfonyl, etc.; m = 0, 1; n = 0-4; p = 0-4; q = 1, 2; p1 = 0-5) and a pharmaceutically acceptable salt thereof, that inhibit farnesyl-protein transferase and ras protein farnesylation.

IT **197911-38-9P 197911-53-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of piperazine-2,5-dione derivs. as inhibitors of farnesyl-protein transferase)

L30 ANSWER 32 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:672280 HCAPLUS
DOCUMENT NUMBER: 127:346413
TITLE: Preparation of N-heterocyclylalkylpiperazinones as farnesyl protein transferase inhibitors
INVENTOR(S): Wei, Dong D.; Williams, Theresa M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Wei, Dong D.; Williams, Theresa M.
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736593	A1	19971009	WO 1997-US5144	19970327 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2249599	AA	19971009	CA 1997-2249599	19970327 <--
AU 9725548	A1	19971022	AU 1997-25548	19970327 <--
AU 706495	B2	19990617		
EP 921801	A1	19990616	EP 1997-917116	19970327 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000507582	T2	20000620	JP 1997-535473	19970327 <--

PRIORITY APPLN. INFO.: US 1996-14593P P 19960403
GB 1996-13460 A 19960627
WO 1997-US5144 W 19970327

OTHER SOURCE(S): MARPAT 127:346413
GI



I

AB R1A1[C(R1a)2]nA2[C(R1a)2]nZ[C(R1b)2]pZ1Z2R [I; A1,A2 = bond, CH:CH, CO, O, CONH, etc.; R = (un)substituted (cyclo)alkyl; R1 = H, (un)substituted heterocyclyl, -aryl, -alk(en)yl; R1a,R1b = H, alkyl, acyl, heterocyclyl, aryl, etc.; Z = bond or (un)substituted heterocyclyl; Z1 = CH2, CO, SO0-2; Z2 = (un)substituted (3-oxo)piperazine-1,4-diyl, -1,4-diazepine-1,4-diyl; n,p = 0-4] were prepd. Thus, (S)-BuCH(NHCO2CMe3)CH2NHCH2CF3 (prepn. given) was cyclocondensed with ClCH2COCl and the deprotected product N-alkylated with 1-(4-cyanobenzyl)imidazole-5-carboxaldehyde (prepn. given) to give, after acidification, I.2HCl. Data for biol. activity of I were given.

IT **198084-17-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-heterocyclylalkylpiperazinones as farnesyl protein transferase inhibitors)

L30 ANSWER 33 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:672278 HCAPLUS
DOCUMENT NUMBER: 127:331503
TITLE: Diazacyloalkanones as inhibitors of farnesyl-protein transferase
INVENTOR(S): Dinsmore, Christopher J.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Dinsmore, Christopher J.
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736591	A1	19971009	WO 1997-US4750	19970327 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2250587	AA	19971009	CA 1997-2250587	19970327 <--
AU 9725879	A1	19971022	AU 1997-25879	19970327 <--
AU 707347	B2	19990708		
EP 900081	A1	19990310	EP 1997-917604	19970327 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001518067	T2	20011009	JP 1997-535357	19970327 <--

PRIORITY APPLN. INFO.: US 1996-14792P P 19960403
GB 1996-10338 A 19960517
WO 1997-US4750 W 19970327

OTHER SOURCE(S): MARPAT 127:331503
GI



I

AB Diazacyloalkanones which inhibit farnesyl-protein transferase and the farnesylation of the oncogene protein Ras were prepd. Thus, 4-imidazolemethanol was tritylated,a acetylated, treated with 4-BrCH2C6H4CN and deblocked to give 1-(4-cyanobenzyl)-5-hydroxymethylimidazole which was oxidized to the aldehyde and treated with 3-ClC6H4N(CH2CO2Me)CH2CH2NH2.HCl to give the piperazinone I. I had an IC50 for inhibition of human FPTase of .1toreq.10 .mu.M.

IT **197853-30-8P 197853-33-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diazacycloalkanones as inhibitors of farnesyl-protein transferase)

L30 ANSWER 34 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:672270 HCAPLUS
DOCUMENT NUMBER: 127:318953
TITLE: Preparation of imidazole derivatives as inhibitors of farnesyl-protein transferase
INVENTOR(S): Bergman, Jeffrey; Dinsmore, Christopher
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Bergman, Jeffrey; Dinsmore, Christopher
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736583	A1	19971009	WO 1997-US5170	19970331 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU,				

IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX,
NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN,
YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, NE, SN, TD, TG

CA 2250143	AA	19971009	CA 1997-2250143	19970331	<--
AU 9725968	A1	19971022	AU 1997-25968	19970331	<--
AU 715604	B2	20000203			
EP 959883	A1	19991201	EP 1997-917711	19970331	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
JP 2000507584	T2	20000620	JP 1997-535483	19970331	<--

PRIORITY APPLN. INFO.:

US 1996-14668P	P	19960403
GB 1996-10654	A	19960521
WO 1997-US5170	W	19970331

GI



I



II

AB The present invention describes compds. (R6)rVA1(CR1a2)nA2(CR1b2)n(WR7)t(CR22)pA3(CR22)pXR3R4 [R1a, R1b, R2 = H, aryl, heterocycle, cycloalkyl, alkenyl, alkynyl, R8O, R9S(O)m, (R8)2NCO, R8CONR8, CN, NO2, (R8)2NC(NR8), R8CO, R8O2C, N3, N(R8)2, R9O2CNR8, (un)substituted alkyl; R3, R4 = H, F, Cl, Br, N(R8)2, CF3, NO2, R8O, R9S(O)m, (R8)2NCO, R8CONH, H2NC(NH), R8CO, R8O2C, N3, CN, R9O2CNR8, alkyl, (un)substituted aryl, (un)substituted heterocyclyl; A3 = NR5S(O)m, S(O)mNR5; m = 0 - 2; R5 = H, (un)substituted aryl, (un)substituted heterocyclyl, (un)substituted cycloalkyl, (un)substituted alkyl; R6, R7 = H, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R8O, R9S(O)m, R8CONR8, CN, NO2, (R8)2NC(NR8), R8CO, R8O2C, N3, N(R8)2, R9O2CNR8, (un)substituted alkyl; R8 = H, alkyl, aryl, aralkyl; R9 = alkyl, aryl; A1, A2 = CH:CH, C.tplbond.C, CO, CONR8, NR8CO, O, NR8, SO2NR8, NR8SO2, S(O)m; A1A2 = bond; X = aryl, heteroaryl; V = H, heterocyclyl, aryl, alkyl, heteroalkyl, alkenyl, provided that V is not H if A1 = S(O)m and V is not H if A1 = bond, n = 0, and A2 = S(O)m; W = heterocyclyl; n, p = 0 - 4; r = 0 - 5, with r = 0 when V = H; t = 0, 1] which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras and to chemotherapeutic compns.. Sulfonamide I.HCl was prepd. from imidazole II (R = OH) via amidation of sulfinyl chloride II (R = SOCl) with 3-ClC6H4CH2NH2 followed by S-oxidn. of sulfonamide II (R = SONHCH2C6H4Cl-3). I.HCl was tested in vitro with Ras peptides, bovine and human FPTase and in vivo with a v-ras line derived from Rat1 or NIH3T3 cells (no data).

IT **197786-21-3P 197786-28-0P 197786-35-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazole derivs. as inhibitors of farnesyl-protein transferase and as antitumor agents)

IT **197786-45-1P**, 3-(4-Cyanobenzyl)-4-[(methylamino)methyl]pyridine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of imidazole derivs. as inhibitors of farnesyl-protein transferase and as antitumor agents)

L30 ANSWER 35 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:641305 HCAPLUS
DOCUMENT NUMBER: 125:275663
TITLE: Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors
INVENTOR(S): Wetterau, John R. II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; et al.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 427 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9626205	A1	19960829	WO 1996-US824	19960201	<--
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2091102	AA	19930907	CA 1993-2091102	19930305	<--
HU 67962	A2	19950529	HU 1993-627	19930305	<--
HU 218419	B	20000828			
JP 06038761	A2	19940215	JP 1993-46499	19930308	<--
EP 584446	A2	19940302	EP 1993-103697	19930308	<--
EP 584446	A3	19950426			
EP 584446	B1	20020619			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
AT 219514	E	20020715	AT 1993-103697	19930308	<--
PT 584446	T	20020930	PT 1993-103697	19930308	
ES 2178640	T3	20030101	ES 1993-103697	19930308	
AU 670930	B2	19960808	AU 1993-34064	19930309	<--
AU 9334064	A1	19930909			
US 5739135	A	19980414	US 1995-472067	19950606	<--
AU 9647631	A1	19960911	AU 1996-47631	19960201	<--
AU 699865	B2	19981217			
EP 886637	A1	19981230	EP 1996-903604	19960201	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
JP 11500442	T2	19990112	JP 1996-525679	19960201	<--
NZ 302055	A	20000228	NZ 1996-302055	19960201	<--
PL 185443	B1	20030530	PL 1996-322003	19960201	
ZA 9601340	A	19970911	ZA 1996-1340	19960220	<--
FI 9703416	A	19970820	FI 1997-3416	19970820	<--
NO 9703821	A	19970820	NO 1997-3821	19970820	<--
LT 4367	B	19980825	LT 1997-152	19970919	<--

PRIORITY APPLN. INFO.:	US 1995-391901	A	19950221	
	US 1995-472067	A	19950606	
	US 1992-847503	A	19920306	
	US 1993-117362	A2	19930903	
	US 1994-284808	B2	19940805	
	WO 1996-US824	W	19960201	

OTHER SOURCE(S): MARPAT 125:275663
GI



I

AB R5Z3NRR6 [R = piperidyl group Q1; R5 = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(en)yl; R5R6 = atoms to form a benzanellated ring; Z3 = CO or SO2; 1 of Z4,Z5 = NR1 and the other = CH2; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SO0-2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepd. as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl-9-fluorenecarboxamide (prepn. given) was alkylated by I(CH2)4OSiMe2CMe3 (prepn. given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (prepn. given) to give title compd. I.

IT **182432-31-1P 182436-32-4P 182437-80-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors)

L30 ANSWER 36 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:75794 HCAPLUS
DOCUMENT NUMBER: 122:55996
TITLE: Studies of cerebral protective agents. VI. Synthesis of novel 4-(4-nitrobenzoyl)pyrimidine and related compounds with antianoxic activity
AUTHOR(S): Ohkubo, Mitsuru; Kuno, Atsushi; Sakai, Hiroyoshi; Sugiyama, Yoshie; Takasugi, Hisashi
CORPORATE SOURCE: New Drug Res. Lab., Fujisawa Pharmaceutical Co., Ltd., Osaka, 532, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (**1994**), 42(6), 1279-85
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Novel pyrimidine derivs., possessing linkages between the aryl group and the pyrimidine nucleus an the C-4 position, were prepd. and tested for antianoxic activity in mice. Among them, 5-(4-methylpiperazin-1-ylcarbonyl)-4-(4-nitrobenzoyl)-2-phenylpyrimidine (FR 76659) (I) possessed significant antianoxic activity (10-100 mg/kg, i.p.) with low acute toxicity (LD50 > 1000 mg/kg, i.p.). Structure-activity relationship in regard to antianoxic activity of this series of compds. were examd.

IT **116904-35-9P 116904-65-5P 116904-66-6P**
159970-99-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of antianoxic cerebral protective agent [(pyrimidinyl)carbonyl]piperazine)

L30 ANSWER 37 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1994:152980 HCAPLUS
DOCUMENT NUMBER:	120:152980
TITLE:	Pyridobenzoxazepine and Pyridobenzothiazepine Derivatives as Potential Central Nervous System Agents: Synthesis and Neurochemical Study
AUTHOR(S):	Liegeois, Jean Francois F.; Rogister, Francoise A.; Bruhwyler, Jacques; Damas, Jacques; Nguyen, Thuy Phuong; Inarejos, Maria Olvido; Chleide, Eric M. G.; Mercier, Michel G. A.; Delarge, Jacques E.
CORPORATE SOURCE:	Laboratory of Medicinal Chemistry, University of Liege, Liege, B-4000, Belg.
SOURCE:	Journal of Medicinal Chemistry (**1994**), 37(4), 519-25 CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB In order to characterize the pharmacol. profile of the different chem. classes of pyridobenzazepine derivs., a series of N-methylpiperazinopyrido[1,4]- and -[1,5]- benzoxa- and benzothiazepine derivs. were prepd. The affinities for D2, D1, 5-HT2, and cholinergic (M) receptors were measured. In comparison to dibenzazepine ref. compds., a strong decrease of the affinities was obsd., less pronounced, however, for the substituted analogs. Oxazepine and thiazepine analogs like clozapine (except 8-chloro-6-(4-methylpiperazin-1-yl)pyrido[2,3-b][1,4]benzoxazepine and 8-chloro-6-(4-methylpiperazin-1-yl)pyrido[2,3-b][1,4]benzothiazepine) were found to be inactive against apomorphine stereotypes. In the open-field test in rats, different mols. showed a high disinhibitory activity as obsd. with anxiolytic drugs. Moreover, 8-chloro-5-(4-methylpiperazin-1-yl)pyrido[2,3-b][1,5]benzoxazepine presented a clozapine-like profile that was confirmed in the behavioral model in dogs and showed most of the behavioral characteristics described for antipsychotic drugs. Its neurochem. profile, in particular the 5-HT2/D2 ratio, was also compatible with atypical antipsychotic activity.

IT **153143-99-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization of)

L30 ANSWER 38 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:147572 HCAPLUS
DOCUMENT NUMBER: 118:147572
TITLE: Preparation of pyridopyrimidine derivatives as antineoplastic agents
INVENTOR(S): Gossett, Lynn Stacy; Shih, Chuan
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 511792	A2	19921104	EP 1992-303715	19920424	<--
EP 511792	A3	19921216			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE					
US 5223503	A	19930629	US 1992-832243	19920207	<--
CA 2066898	AA	19921030	CA 1992-2066898	19920423	<--
JP 05117273	A2	19930514	JP 1992-109565	19920428	<--
PRIORITY APPLN. INFO.:			US 1991-692845	19910429	

OTHER SOURCE(S): MARPAT 118:147572
GI



I



II

AB Title compds. [I; ring A is pyrido or tetrahydropyrido; when A is pyrido, then R1R2 = bond, when A = tetrahydropyrido, R1,R2 = H; R3 = H, alkyl; R4 = (substituted) Ph, biphenylyl, thienyl, pyridyl, naphthyl], were prepd. Thus, 2,4-diamino-6-[2-(3,5-dichlorophenyl)ethenyl]pyrido[2,3-d]pyrimidine was refluxed with aq. NaOH/dioxane to give title compd. II. The latter inhibited CCRF-CEM leukemia with IC50 = 6.4 mg/mL. An oral suspension was prepd contg. II.

IT **145769-31-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for neoplasm inhibitor)

IT **95693-77-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for pyridopyrimidine neoplasm inhibitor)

L30 ANSWER 39 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:571474 HCAPLUS

DOCUMENT NUMBER: 117:171474
TITLE: Cyanopyrazine derivatives and their manufacture
INVENTOR(S): Kojima, Takakazu
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04112877	A2	19920414	JP 1990-232592	19900904 <--

PRIORITY APPLN. INFO.: JP 1990-232592 19900904
OTHER SOURCE(S): CASREACT 117:171474; MARPAT 117:171474
GI



AB Title derivs. I [R = alkyl, aralkyl, cycloalkyl, alkenyl, (substituted) aryl] are manufd. by dimerizing II in the presence of an oxidn. catalyst. Thus, dimerization of II (R = Ph) in 1,2-dimethoxyethane/H2O in the presence of E.C. 1.11.1.7 and H2O2 under ice cooling for 5 h gave 54% I (R = Ph).

IT **143469-44-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by dimerization of diamino(chlorophenylthio)acrylonitrile)

IT **143469-45-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by dimerization of diamino(tolylthio)acrylonitrile)

L30 ANSWER 40 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:426413 HCAPLUS
DOCUMENT NUMBER: 117:26413
TITLE: Studies with polyfunctionally substituted heterocycles: synthesis of new pyridines, naphtho[1,2-b]pyrans, pyrazolo[3,4-b]pyridines and pyrazolo[1,5-a]pyrimidines
AUTHOR(S): Elnagdi, Mohamed Hilmy; Elghandour, Ahmed Hafiz Husein; Ibrahim, Mohamed Kamal Ahmed; Hafiz, Ibrahim Saad Abdel
CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt
SOURCE: Zeitschrift fuer Naturforschung, B: Chemical Sciences (**1992**), 47(4), 572-8
CODEN: ZNBSEN; ISSN: 0932-0776
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A variety of new polyfunctionally substituted pyridines, naphthopyrans and pyrazolopyrimidines were prepd. via reaction of ylidenemalononitriles with thiophenol, thionaphthol, naphthols and aminopyrazoles.

IT **141987-66-8P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and spectra of)

L30 ANSWER 41 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:679818 HCAPLUS
DOCUMENT NUMBER: 115:279818

TITLE: Preparation of piperidine derivatives as neurokinin and substance P antagonists
INVENTOR(S): Emonds-Alt, Xavier; Goulaouic, Pierre; Proietto, Vincenzo; Van Broeck, Didier
PATENT ASSIGNEE(S): SANOFI, Fr.
SOURCE: Eur. Pat. Appl., 84 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 428434	A2	19910522	EP 1990-403125	19901106 <--
EP 428434	A3	19911009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2654100	A1	19910510	FR 1989-14517	19891106 <--
FR 2654100	B1	19920221		
FR 2663329	A1	19911220	FR 1990-7534	19900615 <--
FR 2663329	B1	19921016		
FI 97540	B	19960930	FI 1990-5444	19901102 <--
FI 97540	C	19970110		
CA 2029275	AA	19910507	CA 1990-2029275	19901105 <--
NO 9004802	A	19910507	NO 1990-4802	19901105 <--
NO 177299	B	19950515		
NO 177299	C	19950823		
AU 9065838	A1	19910523	AU 1990-65838	19901105 <--
AU 649973	B2	19940609		
HU 56543	A2	19910930	HU 1990-7027	19901105 <--
US 5317020	A	19940531	US 1990-610093	19901105 <--
IL 111292	A1	19960331	IL 1990-111292	19901105 <--
RU 2084453	C1	19970720	RU 1990-4831627	19901105 <--
RU 2114828	C1	19980710	RU 1993-45020	19901105 <--
ZA 9008881	A	19910828	ZA 1990-8881	19901106 <--
JP 03206086	A2	19910909	JP 1990-300929	19901106 <--
PL 165758	B1	19950228	PL 1990-293823	19901106 <--
PL 165854	B1	19950228	PL 1990-293824	19901106 <--
PL 166565	B1	19950630	PL 1990-287644	19901106 <--
PL 166582	B1	19950630	PL 1990-303827	19901106 <--
IL 96241	A1	19960331	IL 1990-96241	19901115 <--
LV 10713	B	19951020	LV 1993-142	19930225 <--
US 5686609	A	19971111	US 1994-208672	19940311 <--
AU 9459245	A1	19940602	AU 1994-59245	19940331 <--
AU 668018	B2	19960418		
NO 9500239	A	19910507	NO 1995-239	19950123 <--
NO 180193	B	19961125		
NO 180193	C	19970305		
NO 9500240	A	19910507	NO 1995-240	19950123 <--
NO 179580	B	19960729		
NO 179580	C	19961106		
US 5618938	A	19970408	US 1995-479634	19950607 <--
FI 9502956	A	19950615	FI 1995-2956	19950615 <--
FI 9502957	A	19950615	FI 1995-2957	19950615 <--
FI 9800227	A	19980202	FI 1998-227	19980202 <--

PRIORITY APPLN. INFO.:

FR 1989-14517	A	19891106
FR 1990-7534	A	19900615
FI 1990-5444	A	19901102
NO 1990-4802	A	19901105
US 1990-610093	A3	19901105
IL 1990-96241	A3	19901115
US 1994-208672	A3	19940311
FI 1995-2956	A	19950615

OTHER SOURCE(S): MARPAT 115:279818
GI



I

II

AB The title compds. I [m = 1-3; Ar, Ar' = thienyl, (substituted) Ph, etc.; X = H; X' = H, OH; or XX' = oxo, dialkylaminoalkyloxyimino, etc.; Y = N, CX''; X'' = H or X'X'' = carbon-carbon bond; Q = H, alkyl, (CH2)qAm'; q = 2 or 3; Am' = piperidino, 4-benzylpiperidino, etc.; R = H, Me, (CH2)nL; n = 2-6; L = H, amino; T = CO, C(W)NH; W = O, S; Z = H, M, or OM when T = CO; or Z = M when T = C(W)NH; M = H, alkyl, (substituted) phenylalkyl, etc.] were prepd. I are neurokinin and substance P antagonists (no data). Reaction of amine II (Z1 = H) with 2,4-dichlorobenzoyl chloride in the presence of Et3N gave II (Z1 = 2,4-dichlorobenzoyl) isolated as its HCl salt. I are also useful as allergy and inflammation inhibitors (no data).

IT **135956-47-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as neurokinin antagonist)

L30 ANSWER 42 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:506008 HCAPLUS
DOCUMENT NUMBER: 115:106008
TITLE: Preparation of 3-aminomethylquinolines as antiarrhythmic drugs
INVENTOR(S): Cziaky, Zoltan; Korodi, Ferenc; Bilkei-Gorzo, Andras; Peszle, Judit; Frank, Laszlo; Balogh Korik, Piroska; Fabian, Istvan, Mrs.
PATENT ASSIGNEE(S): Alkaloida Vegyeszeti Gyar, Hung.
SOURCE: Hung. Teljes, 18 pp.
CODEN: HUXXBU
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 54348	A2	19910228	HU 1989-1725	19890411 <--
HU 207048	B	19930301		

PRIORITY APPLN. INFO.: HU 1989-1725 19890411
OTHER SOURCE(S): MARPAT 115:106008
GI



I

AB The 3-aminomethylquinoline derivs. I (R1 = Cl, OH, alkoxy, aryloxy, heterocyclyl, etc.; R2, R3 = H, Ph, alkyl, etc.; R2R3 = alkylene; R4, R5 = H, halo, alkyl, alkoxy) are prepd. as antiarrhythmics. A mixt. of 4.24 g 2-chloro-3-chloromethylquinoline, 2.9 g 1-hydroxyethylpiperazine, 10 mL CHCl3 and 10 mL EtOH was stirred at 60.degree. for 6 h, followed by the addn. of 20 mL 2N HCl in EtOH, to give 2-chloro-3-[4-(2-hydroxyethyl)piperazine-1-yl]methyl quinoline-2HCl (II). II (10 mg/L) increased the elec. stimulation threshold and effective refractory period, and decreased the contractility of the isolated rabbit heart left atrium.

IT **135629-48-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and redn. of)

IT **135629-60-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiarrhythmic drug)

L30 ANSWER 43 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:492864 HCAPLUS
DOCUMENT NUMBER: 115:92864
TITLE: Synthesis and biological evaluation of 2-desamino-2-methyl-5,10-dideazatetrahydrofolate
AUTHOR(S): Patil, Sharadbala D.; Kisliuk, R. L.; Gaumont, Y.; Nair, M. G.
CORPORATE SOURCE: Cancer Cent., Univ. South Alabama, Mobile, AL, 36688, USA
SOURCE: Chem. Biol. Pteridines, 1989 Proc. Int. Symp. Pteridines Folic Acid Deriv., 9th (**1990**), Meeting Date 1989, 1043-7. Editor(s): Curtius, Hans-Christoph; Ghisla, Sandro; Blau, Nenad. de Gruyter: Berlin, Fed. Rep. Ger.
CODEN: 57FTAQ
DOCUMENT TYPE: Conference
LANGUAGE: English
GI



I



II

AB A report from a symposium on the prepn. of the title analog (I) of the antitumor agent 5,10-dideazatetrahydrofolate starting from styrylpyridine II. II was a relatively poor inhibitor of GAR-formyltransferase and exhibited only moderate inhibition of Manca human lymphoma cells in culture.

IT **135439-27-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and conversion of, to desamino(methyl)dideazatetrahydrofolate)

L30 ANSWER 44 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:478340 HCAPLUS
DOCUMENT NUMBER: 113:78340
TITLE: Quinoxalines. XXVII. The cyanation of 2-substituted quinoxaline 4-oxides with trimethylsilyl cyanide
AUTHOR(S): Iijima, Chihoko; Miyashita, Akira
CORPORATE SOURCE: Sch. Pharm. Sci., Univ. Shizuoka, Shizuoka, 422, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1990), 38(3), 661-3
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:78340
GI


I

II

III

AB The deoxycyanation of 2-substituted quinoxaline 4-oxides I (R = Ph, MeO, EtO, Me2CH, Me3C, Et, Me, EtO2C, cyano, Cl, 4-MeC6H4SO2, etc.) with Me3SiCN in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene gave the corresponding 3-substituted 2-quinoxalinecarbonitriles II. However, in the case of I (R = 4-MeC6H4SO2) the substitution with cyanide ion proceeded together with deoxycyanation to give 2,3-quinoxalinedicarbonitrile (III).
IT **128478-59-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L30 ANSWER 45 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:459240 HCAPLUS
DOCUMENT NUMBER: 113:59240
TITLE: Preparation of pyrazine and 1,4-diazepine derivatives
INVENTOR(S): Yagihara, Tomio; Matsui, Nobuo; Hamamoto, Isami; Hatano, Hiromi; Tazaki, Seiji
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02049775	A2	19900220	JP 1988-233628	19880920 <--

PRIORITY APPLN. INFO.: JP 1988-120729 19880519
OTHER SOURCE(S): MARPAT 113:59240
GI



AB The title compds. [I, more specifically II, III, and IV; R = (heterocyclyl)alkyl, aralkyl, cycloalkyl, alkenyl, (un)substituted aryl; n = 0, 1, 2; R1 = H, cyano, CONH2, (un)substituted CO2H; R2 = (alkyl)aryl, alkoxycarbonyl, oxo; m = 0, 1, 2; or R2R2 completing a ring; Z = CC or CCC; R4, R5 = H, alkyl, aralkyl, aryl, alkoxycarbonyl; or R4R5 completing a ring; R7, R8 = alkyl, aryl; or R7R8 completing a ring], useful as intermediates for pharmaceuticals, agrochems., perfumes, dyes, or polymers, are prepd. by cyclocondensation of (1) RSC(NH2):C(NH2)CN (V) with R4COCOR5 to II, (2) V with R6COCOR6 (R6 = Cl, imidazolyl) to III, and (3) V with R7COCH2COR8 to IV. Thus, benzil was added to a soln. of V in EtOH. After stirring 2 h at room temp., pptd. crystals were removed by filtration and recrystd. from benzene-n-hexane to give 70% II (R = Ph, R4 = R5 = Ph). Addnl. 42 I were prepd.

IT **128169-37-9P 128169-38-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by cyclocondensation of diaminoacrylonitrile and dioxo compd.)

L30 ANSWER 46 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:570451 HCAPLUS
DOCUMENT NUMBER: 109:170451
TITLE: Preparation of pyrimidine derivatives as drugs for treating disease and disorders of cerebral blood vessels
INVENTOR(S): Takatani, Takao; Takasugi, Hisashi; Kuno, Atsushi; Sugiyama, Yoshie; Sakai, Hiroyoshi; Okubo, Mitsuru
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63107966	A2	19880512	JP 1987-124326	19870520 <--

PRIORITY APPLN. INFO.: JP 1986-117800 19860522
OTHER SOURCE(S): CASREACT 109:170451; MARPAT 109:170451
GI



I

AB The title compds. [I; Ar = (nitro or habalkyl)aryl, fused benzene-heterocyclyl contg. N or O; X = bond, lower hydroxyalkylene, lower alkenylene, NH, S, CO; R1 = (esterified) CO2H, lower hydroxyalkyl, lower haloalkyl, (N-substituted) CONH2 or lower aminoalkyl; R2 = H, lower alkyl; optionally R1R2 completing (substituted) N-contg. heterocycle; R3 = aryl], were prepd. as drugs e.g. for treating apoplexy. A mixt. of 6-bromomethyl-4-(3-nitrophenyl)2-phenyl-5-pyrimidinecarboxylic acid Me ester and Me2NCH2CHNH2 in iso-PrOH was stirred at 70.degree. for 1 h to give 6-[2-(dimethylamino)ethyl]4-(3-nitrophenyl)-5-oxo-2-phenyl-6,7-dihydropyrrolo[3,4-d]pyrimidine. The latter at 10 mg/kg i.p. extended the survival time of mice from 28.2 .+-. 1.1 s (control) to 33.6 .+-. 2.9 s when the mice were exposed to 100% N atm.

IT **116904-34-8P 116904-35-9P 116904-65-5P**
116904-66-6P 116904-78-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as drug for treating apoplexy)

L30 ANSWER 47 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:576424 HCAPLUS
DOCUMENT NUMBER: 107:176424
TITLE: Synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) and analogs
AUTHOR(S): Taylor, Edward C.; Wong, George S. K.; Fletcher, Stephen R.; Harrington, Peter J.; Beardsley, G. Peter; Shih, Chuan J.
CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, 08544, USA
SOURCE: Chem. Biol. Pteridines, 1986, Pteridines Folic Acid Deriv., Proc. Int. Symp. Pteridines Folic Acid Deriv.: Chem., Biol. Clin. Aspects, 8th (**1986**), 61-4. Editor(s): Cooper, Bernard A.; Whitehead, V. Michael. de Gruyter: Berlin, Fed. Rep. Ger.
CODEN: 55HGAH
DOCUMENT TYPE: Conference
LANGUAGE: English
OTHER SOURCE(S): CASREACT 107:176424
GI



I



II



III



IV

AB DDATHF (I) was prepd. in 14 steps from thiocyanoacetamide and .beta.-ethoxymethacrolein. Two of the key steps were the Wittig reaction of phosphonium compd. II with tert-Bu p-formylbenzoate to give Wittig product III and the guanidine cyclization of III to give pyrido[2,3-d]pyrimidine IV. The glutamic acid moiety was introduced as di-Et glutamate. I was obtained as a mixt. of 2 diastereomers, which were sepd. via fractional crystn. of d-10-camphorsulfonic acid salts. The 10-Me analog of I was prepd. similarly. I and its analogs are potent inhibitors of cell growth in culture without significant effect on dihydrofolate reductase or thymidylate synthase.

IT **105580-38-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(Wittig reaction of, with tert-Bu p-acetylbenzoate)

IT **105580-42-5P 105580-43-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT **95693-77-9P 95693-78-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for dideazatetrahydrofolic acid)

L30 ANSWER 48 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:33470 HCAPLUS
DOCUMENT NUMBER: 106:33470
TITLE: N-[(Pyridopyrimidinylethyl)benzoyl]glutamic acid derivatives
INVENTOR(S): Taylor, Edward C.; Beardsley, George Peter; Harrington, Peter J.; Fletcher, Stephen R.
PATENT ASSIGNEE(S): Princeton University, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8605181	A1	19860912	WO 1986-US368	19860224 <--
W: AU, DK, HU, JP, KR, SU				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
ZA 8601235	A	19861029	ZA 1986-1235	19860219 <--

AU 8655108	A1	19860924	AU 1986-55108	19860224 <--
AU 578813	B2	19881103		
EP 215063	A1	19870325	EP 1986-901675	19860224 <--
EP 215063	B1	19931103		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
HU 41785	A2	19870528	HU 1986-2011	19860224 <--
HU 196202	B	19881028		
JP 62502535	T2	19871001	JP 1986-501296	19860224 <--
JP 08022860	B4	19960306		
AT 96790	E	19931115	AT 1986-901675	19860224 <--
US 4684653	A	19870804	US 1986-835457	19860303 <--
ES 552684	A1	19870316	ES 1986-552684	19860305 <--
IL 78059	A1	19890630	IL 1986-78059	19860306 <--
CA 1276637	A1	19901120	CA 1986-503509	19860307 <--
CN 86101475	A	19870121	CN 1986-101475	19860308 <--
CN 1016174	B	19920408		
DK 8604721	A	19861219	DK 1986-4721	19861002 <--
DK 168666	B1	19940516		
ES 557174	A1	19871216	ES 1986-557174	19861031 <--
SU 1676449	A3	19910907	SU 1986-4028461	19861103 <--
US 4845216	A	19890704	US 1987-74623	19870717 <--
US 4927828	A	19900522	US 1988-220944	19880628 <--
US 5026851	A	19910625	US 1989-341497	19890421 <--
CA 1308411	A2	19921006	CA 1990-615803	19900731 <--
JP 08193084	A2	19960730	JP 1995-228382	19950905 <--

PRIORITY APPLN. INFO.:	US 1985-709622	19850308
	EP 1986-901675	19860224
	WO 1986-US368	19860224
	US 1986-835457	19860303
	CA 1986-503509	19860307
	US 1986-871539	19860606
	US 1987-74623	19870717

OTHER SOURCE(S): CASREACT 106:33470

GI



I



II

AB N-[(Pyridopyrimidinylalkyl)benzoyl]-L-glutamic acids I (R = H; R1 = NH2, OH; R2 = H, Me, Et) and their 5,6,7,8-tetradehydro analogs were prepd. as neoplasm inhibitors. Thus, a triphenyl(3-pyridinylmethyl)phosphonium bromide deriv. underwent a Wittig reaction with 4-HCOC6H4CO2CMe3, followed by ammonolysis and cyclocondensation with guanidine to give [(pyridopyrimidinyl)ethenyl]benzoate II. The latter was converted in 6 steps to L-I (R = Et, R1 = OH, R2 = H), which was deesterified with CF3CO2H to give L-I (R = R2 = H, R1 = OH) (III). In mice 50 mg III/kg/day i.p. for 8 days gave 100% inhibition of, e.g., lymphosarcoma 6C3HED.

IT **87373-60-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(bromination of)

IT **95693-77-9P 105580-38-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(prepn. and Wittig reaction of, with formylbenzoates and acetophenones)

IT **88553-19-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and Wittig reaction of, with phosphines and formylbenzoate ester)

IT **95674-62-7P 105580-39-0P 105580-40-3P 105580-42-5P 105580-43-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and ammonolysis of)

L30 ANSWER 49 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1985:504912 HCAPLUS
DOCUMENT NUMBER: 103:104912
TITLE: Synthesis and diuretic activity of pyrido[2,3-d]pyrimidones and related compounds
AUTHOR(S): Monge, Antonio; Martinez-Merino, Victor; Cenarruzabeitia, Edurne; Lasheras, Berta; Fernandez-Alvarez, Eldiberto
CORPORATE SOURCE: Dep. Quim. Org. Farmac., Spain
SOURCE: European Journal of Medicinal Chemistry (**1985**), 20(1), 61-6
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:104912
GI



I

AB Dipyridopyrimidines I (R = H, 2-chloronicotinamido; R1 = H, Me; R2 = H, Me, 2-chloronicotinamido, NH2), which were prepd., showed diuretic activity. A mixt. of 2-chloronicotinoyl chloride and 2-aminopyridine in PhMe was heated to give I (R = R1 = R2 = H).

IT **97936-26-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclocondensation of)

IT **97936-34-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and diuretic activity of)

IT **97936-25-9P 97936-27-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L30 ANSWER 50 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1985:406676 HCAPLUS
DOCUMENT NUMBER: 103:6676
TITLE: Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-

tetrahydroaminopterin
AUTHOR(S): Taylor, Edward C.; Harrington, Peter J.; Fletcher, Stephen R.; Beardsley, G. Peter; Moran, Richard G.
CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, 08544, USA
SOURCE: Journal of Medicinal Chemistry (**1985**), 28(7), 914-21
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:6676
GI



I

AB 5,10-Dideazaaminopterin (I) and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin were prepd. from pyridine precursors. These compds. exhibit significant in vivo activity against L1210 leukemia that is comparable to that obsd. with methotrexate.

IT **87373-60-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(bromination of)

IT **95674-62-7P 95693-78-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and amination of)

IT **95693-77-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with ethoxycarbonylbenzaldehyde)

IT **88553-19-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with triphenylphosphine)

L30 ANSWER 51 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1984:455505 HCAPLUS
Correction of: 1984:103829
DOCUMENT NUMBER: 101:55505
Correction of: 100:103829
TITLE: Synthesis and biological activity of L-5-deazafolic acid and L-deazaaminopterin: synthetic strategies to 5-deazapteridines
AUTHOR(S): Taylor, Edward C.; Palmer, David C.; George, Thomas J.; Fletcher, Stephen R.; Tseng, Chi Ping; Harrington, Peter J.; Beardsley, G. Peter; Dumas, Donald J.; Rosowsky, Andre; Wick, Michael
CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, 08544, USA
SOURCE: Journal of Organic Chemistry (**1983**), 48(25), 4852-60
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB L-5-Deazafolic acid (I, R = R1 = H) was prepd. by the reductive amination of deazapterin II (R = Ac) with p-H2NC6H4CO-L-Glu(OMe)-OMe (III), followed by the sapon. of the resulting I (R = Ac, R1 = Me). L-5-Deazaaminopterin (IV) was prepd. similarly from 5-deazapteridine V and III. Pyrimidine VI was cyclized with HC(OMe)3 to give II (R = H), which was acetylated to give II (R = Ac). NCCH2CSNH2 was cyclized with EtOCH:CMeCO to give pyridinethione VII, which was converted to V in several steps in which the key was the cyclization of pyridine VIII with guanidine to give the di-Me acetal of V. 3-Formylthietane and its di-Me and ethylene acetals were prepd. as synthons for the pyridine ring of deazapteridines IX (R2 = R3 = H, R2R3 = bond). 2,4-Diamino-6-methyl-5-deazapteridine was prepd., but functionalization of the C-6 Me group was not possible. I is equipotent with methotrexate as an inhibitor of bovine liver dihydrofolate reductase and of L1210 murine leukemia cells.

IT **87373-63-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acetalization of)

IT **87373-64-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and aminolysis of)

IT **87373-60-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and bromination of)

IT **87373-87-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of)

IT **87373-62-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with nitrosodimethylaniline)

IT **87373-61-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with pyridine)

L30 ANSWER 52 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1984:103829 HCAPLUS
DOCUMENT NUMBER: 100:103829
TITLE: Synthesis and biological activity of L-5-deazafolic acid and L-deazaaminopterin: synthetic strategies to 5-deazapteridines
AUTHOR(S): Taylor, Edward C.; Palmer, David C.; George, Thomas J.; Fletcher, Stephen R.; Tseng, Chi Ping; Harrington, Peter J.; Beardsley, G. Peter
CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, 08544, USA
SOURCE: Journal of Organic Chemistry (1983), 48(25), 4852-60
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB L-5-Deazafolic acid (I, R = R1 = H) was prepd. by the reductive amination of deazapterin II (R = Ac) with p-H2NC6H4CO-L-Glu(OMe)-OMe (III), followed by the sapon. of the resulting I (R = Ac, R1 = Me). L-5-Deazaaminopterin (IV) was prepd. similarly from 5-deazapteridine V and III. Pyrimidine VI was cyclized with HC(OMe)3 to give II (R = H), which was acetylated to give II (R = Ac). NCCH2CSNH2 was cyclized with EtOCH:CMeCO to give pyridinethione VII, which was converted to V in several steps in which the key step was the cyclization of pyridine VIII with guanidine to give the di-Me acetal of V. 3-Formylthietane and its di-Me and ethylene acetals were prepd. as synthons for the pyridine ring of deazapteridines IX (R2 = R3 = H, R2R3 = bond). 2,4-Diamino-6-methyl-5-deazapteridine was prepd., but functionalization of the C-6 Me group was not possible. I is equipotent with methotrexate as an inhibitor of bovine liver dihydrofolate reductase and of L1210 murine leukemia cells.

IT **87373-63-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acetalization of)

IT **87373-64-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and aminolysis of)

IT **87373-60-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and bromination of)

IT **87373-87-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of)

IT **87373-62-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with nitrosodimethylaniline)

IT **87373-61-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with pyridine)

L30 ANSWER 53 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1984:68665 HCAPLUS
DOCUMENT NUMBER: 100:68665
TITLE: Synthesis and biological activity of 5-deazafolic acid and 5-deazaaminopterin
AUTHOR(S): Taylor, Edward C.; Tseng, Chi Ping; Harrington, Peter J.; Beardsley, G. Peter; Rosowsky, Andrew; Wick, Michael
CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, USA
SOURCE: Chem. Biol. Pteridines, Proc. Int. Symp. Pteridines Folic Acid Deriv.: Chem., Biol. Clin. Aspects, 7th (**1983**), Meeting Date 1982, 115-19. Editor(s): Blair, John A. de Gruyter: Berlin, Fed. Rep. Ger.
CODEN: 50NHAH
DOCUMENT TYPE: Conference
LANGUAGE: English
GI



I

AB Title compds. I (R = H, R1R2 = O; RR1 = bond, R2 = NH2) were prepd. by multistep procedures starting with the resp. cyclocondensation of 2,4-diamino-6(1H)-pyrimidinone with HC(CHO)3 and of NCCH2C(S)NH2 with EtOCH:CMeCHO. 5-Deazafolic acid is a potent inhibitor of dihydrofolate reductase. The cytotoxic activities of I were also examd.

IT **87373-63-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acetylation with methanol)

IT **87373-64-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and aminolysis of)

IT **87373-60-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and bromination of)

IT **88553-20-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and elimination reaction of)

IT **88553-19-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction with pyridine)

IT **87373-61-3P 88566-70-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L30 ANSWER 54 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1976:421451 HCAPLUS
DOCUMENT NUMBER: 85:21451
TITLE: Psychotropic 6-piperazino-5,6-dihydrobenzo(b)pyrido(3,2-f)thiepins
INVENTOR(S): Protiva, Miroslav; Bartl, Vaclav; Metysova, Jirina
PATENT ASSIGNEE(S): Czech.
SOURCE: Czech., 5 pp.
CODEN: CZXXA9
DOCUMENT TYPE: Patent
LANGUAGE: Czech
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 159522	B	19750131	CS 1972-7366	19721101 <--

PRIORITY APPLN. INFO.: CS 1972-7366 19721101
GI



I

AB The title compds. I [R1 = Cl or iso-Pr; R2 = H, Me, (CH2)3OH or CO2Et] were prepd. I had central nervous system depressant, cataleptic, and anticonvulsant activity (no data). Heating of 2-chloronicotinic acid (II) with 4-ClC6H4SH gave 2-(4-chlorophenylthio)nicotinic acid which was reduced with NaAl(OCH2CH2OMe)2H2 to 2-(4-chlorophenylthio)-3-pyridylcarbinol. Treatment with SOCl2 gave the HCl salt of 2-(4-chlorophenylthio)-3-chloromethylpyridine. The free base reacted with KCN in aq. EtOH giving 2-(4-chlorophenylthio)-3-pyridylacetonitrile which was hydrolyzed with KOH to 2-(4-chlorophenylthio)-3-pyridylacetic acid. Cyclization with polyphosphoric acid yielded 8-chlorobenzo[b]pyrido[3,2-f]thiepin-6(5H)-one. Redn. with NaBH4 gave the 6-hydroxy-5,6-dihydro analog which was transformed with SOCl2 to 6,8-dichloro-5,6-dihydrobenzo[b]pyrido[3,2-f]thiepin HCl. Substitution reactions with 1-methyl-, 1-(3-hydroxypropyl)- and 1-(ethoxycarbonyl)piperazine gave I [R1 = Cl, R2 = Me, (CH2)3OH, and CO2Et]. The latter was hydrolyzed with KOH to I (R1 = Cl, R2 = H). A similar synthesis starting from the reaction of II with 4-(iso-Pr)C6H4SH gave in nine steps I (R1 = iso-Pr, R2 = Me).

IT **51723-89-8P 51723-90-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of)

L30 ANSWER 55 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1974:82882 HCAPLUS
DOCUMENT NUMBER: 80:82882
TITLE: Neurotropic and psychotropic agents. LXV. 8-Chloro and 8-isopropyl-6-piperazinobenzo[b]pyrido[3,2-f]thiepins
AUTHOR(S): Bartl, V.; Metysova, J.; Protiva, M.
CORPORATE SOURCE: Res. Inst. Pharm. Biochem., Prague, Czech.
SOURCE: Collection of Czechoslovak Chemical Communications (**1973**), 38(9), 2778-87
CODEN: CCCCAK; ISSN: 0010-0765
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The title compds., esp. I-IV, were prepd. as potential neuroleptics. Reaction of 2-chloronicotinic acid with 4-chloro- and 4-isopropylbenzenethiol gave 2-(4-chlorophenylthio)- and 2-(4-isopropylphenylthio)nicotinic acid which were converted in 4 steps to 2-(4-chlorophenylthio)- and 2-(4-isopropylphenylthio)-3-pyridineacetic acid. Cyclization with polyphosphoric acid yielded 8-chloro- (V) and 8-isopropylbenzo-[b]pyrido[3,2-f]thiepin-6(5H)-one (VI). V and VI treated with 1-methylpiperazine (VII) and TiCl4 inC6H6 gave I and II. V and VI were reduced with NaBH4 and the alcs. obtained converted with SOCl2 to 6,8-dichloro-5,6-dihydrobenzo[b]pyrido[3,2-f]-thiepin (VIII) and 6-chloro-8-isopropyl-5,6-dihydrobenzo[b]-pyrido[3,2-f]thiepin (IX). VIII and IX treated with VII, 1-(3-hydroxypropyl)piperazine and 1-(ethoxycarbonyl)piperazine gave III, IV, and the corresponding analogs. 6-[4-(Ethoxycarbonyl)-1-piperazinyl]-8-chloro-5,6-dihydrobenzo[b]pyrido[3,2-f]thiepin was hydrolyzed to 6-1-piperazinyl-8-chloro-5,6-dihydrobenzo[b]-pyrido[3,2-f]thiepin.
IT **51723-89-8P 51723-90-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

L30 ANSWER 56 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:488314 HCAPLUS
DOCUMENT NUMBER: 77:88314
TITLE: Pesticidal 2-substituted-3-cyano-5-nitropyridines
INVENTOR(S): Freeman, Peter F. H.
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3674877	A	19720704	US 1970-42858	19700602 <--

PRIORITY APPLN. INFO.: US 1970-42858 19700602
GI For diagram(s), see printed CA Issue.
AB 5-Nitronicotinonitrile derivs. (I, R = Cl, OH, amino, arylamido, alkylthio, arylthio, aryldithio, aryloxy), 3-cyano-1-methyl-5-nitro-2-pyridone, and 2-chloro-3-cyano-1-ethyl-5-nitropyridinium fluoroborate were prepd. from the dihydropyridine derivs. (II, R1 = H, Me; X = O, S) obtained by condensation of NaC(NO2)(CHO)2 with NCCH2CXNHR1. Thus, I (R = Cl) was prepd. by treating II (R1 = H, X = O) with PCl5 and POCl3. I (R = NHCH2CO2Et) was prepd. by treating I (R = Cl) with EtO2CCH2NH2.HCl and NaOAc. Many of the above 32 compds. were agricultural fungicides and insecticides. Thus, I (R = pyrrolidino) at 125 ppm killed Aphis fabae and Megoura vicia; I (R = Cl) at 500 ppm was more effective than Thiram against Pythium ultimum.
IT **31309-28-1P 31309-29-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L30 ANSWER 57 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:126788 HCAPLUS
DOCUMENT NUMBER: 76:126788
TITLE: Antiedematous 2-(phenylthio)- and 2-phenoxypyridines
INVENTOR(S): Blum, Jean
SOURCE: Fr. Demande, 12 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2068429	A5	19710827	FR 1969-39113	19691114 <--
FR 2068429	B1	19730112		

PRIORITY APPLN. INFO.: FR 1969-39113 19691114
GI For diagram(s), see printed CA Issue.
AB Re-fluxing nicotinamide 1-oxide with POCl3 gave I (R = Cl) (II). Refluxing II with aq. EtOH-PhOK gave I (R = PhO) (III). Similarly prepd. were I (R = PhS, 2,3-Me2C6H3S, m-F3CC6H4S). Refluxing III with aq. EtOH-KOH gave 2-phenoxynicotinic acid (IV); other nitriles were similarly hydrolyzed. Heating I (R = PhS) with NaN3, LiCl, and NH4Cl in HCONMe2 at 130.degree. gave 2-(phenylthio)-3-(5-tetrazolyl)pyridine (V). At 100 mg/-kg, III gave 42% inhibition of carrageenan induced edema in rat paws.
IT **35620-70-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L30 ANSWER 58 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1971:99891 HCAPLUS
DOCUMENT NUMBER: 74:99891
TITLE: Pesticidal 2-substituted 3-cyano-5-nitropyridines
INVENTOR(S): Barton, John E. D.; Freeman, Peter F. H.
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: Ger. Offen., 45 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2029079	A	19710121	DE 1970-2029079	19700612 <--
ZA 7003779	A	19720126	ZA 1970-3779	19700603 <--
NL 7008411	A	19701215	NL 1970-8411	19700610 <--
FR 2046711	A7	19710312	FR 1970-21497	19700611 <--
FR 2046711	B3	19730316		
ES 380702	A1	19720816	ES 1970-380702	19700612 <--
BR 7019726	A0	19730220	BR 1970-219726	19700612 <--

PRIORITY APPLN. INFO.: GB 1969-29864 19690612
GI For diagram(s), see printed CA Issue.
AB Compns. of the new fungicidal (esp. active against fungi originating in the soil), in some cases insecticidal, nonherbicidal title compds. (I), II, and III for plants are reported. Thus, refluxing 3-cyano-5-nitro-2-pyridone in PCl5-POCl3 gave I (R = Cl) (IV). Refluxing IV, Et glycinate-HCl, and AcONa in aq. EtOH gave I (R = NHCH2CO2Et). Among 29 compds. similarly prepd. or described were I (R given): NH2, NHPh, NMe2, NHBz, SPr-iso, SCH2CH2CN, SCH2CO2Et, SCH2Ph, OC6H4Cl-p, II, and III.
IT **31309-28-1P 31309-29-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L30 ANSWER 59 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1969:501819 HCAPLUS
DOCUMENT NUMBER: 71:101819
TITLE: Unusual leaving groups in cyclizations of the quinoxaline series. II
AUTHOR(S): Dahn, Hans; Nussbaum, Jeannine
CORPORATE SOURCE: Univ. Lausanne, Lausanne, Switz.
SOURCE: Helvetica Chimica Acta (**1969**), 52(6), 1661-71
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 71:101819
GI For diagram(s), see printed CA Issue.
AB 2,3-(RR1-Substituted)quinoxalines (I) (where R = H, OH, Cl, CN, CO2H, CONH2, CH2Ph, or Bz; and R1 = p-MeOC6H4 or Ph) were cyclized with HONH2 to give 3-(R1-substituted)isoxazolo [4,5-b]quinoxalines (II) and with PhNHNH2 to give 3-(R1-substituted)pyrazolo[4,5-b]quinoxalines (III). I (where R = Me or Ph) were not cyclized. The displacement of H in I (R = H) is explained in terms of the osazone formation theory.
IT **23773-91-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L30 ANSWER 60 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1965:51669 HCAPLUS
DOCUMENT NUMBER: 62:51669

ORIGINAL REFERENCE NO.: 62:9138a-e
TITLE: 4-Azathioxanthene derivatives
INVENTOR(S): Jucker, E.; Ebnoether, A.
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: 11 pp.; Addn. to Belg. 611,216 (CA 58, 1461g).
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
BE 638971		19640421	BE		<--
FR AD84820			FR		
FR M3323			FR		
NL 299465			NL		

PRIORITY APPLN. INFO.: CH 19621023

GI For diagram(s), see printed CA Issue.

AB The title compds. of general formula Ia are useful as antihistamines, serotonine antagonists, antiasthmatics, neuroleptics, or antidepressants. Thus, a mixt. of 78 g. 2-chloronicotinic acid and 145 g. p-chlorothiophenol was heated 3 hrs. at 170.degree. and cooled, the reaction product treated with 500 ml. ether and 1 l. satd. NaHCO3 soln. to dissoln., the ether layer extd. with NaHCO3 soln., and the combined aq. exts. adjusted to pH 5 with AcOH to ppt. 2-(p-chlorophenylthio)-3-carboxypyridine (I), m. 216-17.degree. (MeOH). A mixt. of 35 g. I and 350 g. polyphosphoric acid was heated at 150.degree. 1 hr. and at 180.degree. 2 hrs., cooled to about 100.degree., and drowned with good agitation in 1500 ml. H2O, the ppt. filtered off, agitated 10 min. with 200 ml. 10% caustic soda, filtered off again, washed well with H2O, and dried to give 7-chloro-4-azathioxanthone (II), m. 194-5.degree. (AcOH). Mg turnings (2.43 g.) activated with iodine were covered with 10 ml. tetrahydrofuran (THF), 0.3 ml. ethylene bromide was added to start the reaction, a soln. of 14.7 g. 1-methyl-4-chloropiperidine in 25 ml. abs. THF added dropwise at such a rate that the reaction mixt. stayed at a boil, the mixt. heated 1-2 hrs. until most of the Mg was in soln. and cooled, 12.4 g. II added portionwise at 20-5.degree., the mixt. agitated 20 min. at room temp., poured into 300 ml. 10% NH4Cl, and extd. with CH2Cl2, and the ext. dried over MgSO4 and evapd. to give 4-aza-7-chloro-9-(1-methyl-4-piperidyl)thioxanthydrol (III), m. 225-6.degree. (Me2CO). A mixt. of 10 g. III, 25 ml. H2O, and 75 ml. H2SO4 was heated 20 min. to 140.degree. and drowned in 500 ml. ice H2O, the soln. made alk. with 50% caustic soda and extd. with CH2Cl2, and the ext. dried over K2CO3 and evapd. to give 4-aza-7-chloro-9-(1-methyl-4-piperidylidene)thioxanthene, m. 150-2.degree. (Me2CO). Similarly prepd. were the following 4-azathioxanthones (substituents and m.p. given): 7-Br, 190-3.degree. (AcOH); 7-Me, 153-4.degree. (Me2CO); 3,7-MeCl, 235-6.degree. (AcOH). Also prepd. were 4-azathioxanthydrols (same data): 7-bromo-9-(1-methyl-4-piperidyl), 227-37.degree. (decompn.)(EtOH); 7-methyl-9-(1-methyl-4-piperidyl), 185-6.degree. (EtOH); 3-methyl-7-chloro-9-(1-methyl-4-piperidyl), 208-10.degree. (Me2CO); 7,9-Cl-[Me2N(CH2)3], 175-7.degree. (EtOAc); 7,9-Me[Me2N(CH2)3, 172-4.degree. (Me2CO). The following 4-azathioxanthenes were also prepd. (same data): 7-bromo-9-(1-methyl-4-piperidylidene), 166-8.degree. (Me2CO); 7-methyl-9-(1-methyl-4-piperidylidene, 130-2.degree. (hexane); 3-methyl-7-chloro-9-(1-methyl-4-piperidylidene), 155-6.degree. (Me2CO); 7,9-Cl(Me2NCH2CH2CH:), - [fumarate m. 179-81.degree. (decompn.)(MeOH)]; 7,9-Me(Me2NCH2CH2CH:), - [H fumarate m. 195-6.degree. (decompn.)(MeOH)]. The following IV (used as intermediates) were also prepd. (R, R1, R2, and m.p. given): BrCO2H, H, 220-1.degree. (MeOH); Me, CO2H, H, 217-18.degree. (EtOH); Cl, CN, Me, 135-6.degree. (Me2CO); Cl, CO2H, Me, 212-13.degree..

IT **955-63-5**, Nicotinonitrile, 2-[(p-chlorophenyl)thio]-6-methyl-
(prepn. of)

L30 ANSWER 61 OF 61 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1961:38071 HCAPLUS
DOCUMENT NUMBER: 55:38071
ORIGINAL REFERENCE NO.: 55:7425a-e
TITLE: Reductones and 1,2,3-tricarbonyl compounds. XIX. .gamma.-Aryl-.alpha.,.beta.-dioxobutyramides
AUTHOR(S): Dahn, H.; Rotzler, G.
CORPORATE SOURCE: Univ. Basel, Switz.
SOURCE: Helvetica Chimica Acta (**1960**), 43, 1555-61
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 55:38071
GI For diagram(s), see printed CA Issue.
AB cf. CA 54, 19635d. Refluxing I (obtained from aromatic or heterocyclic aldehydes with glyoxal and KCN; Dahn, et al., CA 49, 13209b) 1 hr. with 40% AcOH or 0.01N H2SO4 or heating I with H2O and Amberlite IR (H form) to 70.degree. gives RCH2COCOCONH2.H2O (II) and lactones (III). Oxidn. of II with 1 mole HIO4 gives the RCH2CO2H, NH3, and (COOH)2; condensation of II with o-phenylenediamine gives 3-substituted-quinoxaline-2-carboxamide, which can be hydrolyzed to the free acid and decarboxylated to 2-substituted-quinoxaline. Phenylhydrazine reacts with the middle CO group of II to form a phenylhydrazone, and with the oxo and amide groups to form a pyrazolone. The middle CO group is hydrated; in the presence of MeOH, a half acetal, RCH2COC(OMe)(OH)CONH2 is formed. The following II are prepd. (R given): Ph, m. 108-10.degree. (decompn.), .lambda. 295 m.mu. (all in EtOH); o-ClC6H4, .lambda. 305 m.mu.; p-MeOC6H4, m. 110-14.degree. (decompn.). 3-Arylquinoxaline-2-carboxamides prepd. were (aryl group given): PhCH2, m. 163.degree.; o-ClC6H4CH2, m. 193.degree.; p-MeOC6H4CH2, m. 165.degree.. 3-Benzylquinoxaline-2-carboxylic acid m. 145.degree. (decompn.); 2-benzylquinoxaline m. 38.5.degree., b.12 208-10.degree.; 2-(o-chlorobenzyl)quinoxaline m. 55.degree., b.0.01 114-16.degree.; 1-phenyl-3-benzyl-4-phenylazo-5-pyrazolone (IV) m. 153-4.degree.; the 3-(o-chlorobenzyl) analog of IV m. 166-9.degree.. Infrared spectral data are given.
IT **101569-95-3**, 2-Quinoxalinecarboxamide, 3-p-methoxybenzyl-
(prepn. of)

=>
=>

=> select hit rn 130 1-61
E121 THROUGH E240 ASSIGNED

=> fil reg
FILE 'REGISTRY' ENTERED AT 11:34:10 ON 19 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2004 HIGHEST RN 683203-75-0
DICTIONARY FILE UPDATES: 18 MAY 2004 HIGHEST RN 683203-75-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
=>

=> d his l31

(FILE 'HCAPLUS' ENTERED AT 11:28:29 ON 19 MAY 2004)
SELECT HIT RN L30 1-61

FILE 'HCAPLUS' ENTERED AT 11:33:30 ON 19 MAY 2004
SELECT HIT RN L30 1-61

FILE 'REGISTRY' ENTERED AT 11:34:10 ON 19 MAY 2004
L31 120 S E121-E240

=>
=>

=> d ide can 131 1-120

L31 ANSWER 1 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **443927-04-6** REGISTRY
CN Benzonitrile, 4-[[3-[[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-2-oxo-1H-3-benzazepin-1-yl]amino]methyl]-4-pyridinyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H30 N4 O . 2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 443927-03-5
CMF C32 H30 N4 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:125099

L31 ANSWER 2 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **443927-03-5** REGISTRY
CN Benzonitrile, 4-[[3-[[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-2-oxo-1H-3-benzazepin-1-yl]amino]methyl]-4-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C32 H30 N4 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:125099

L31 ANSWER 3 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **443926-07-6** REGISTRY
CN Benzonitrile, 4-[[3-[[[(4S)-2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-3-oxo-1H-2-benzazepin-4-yl]amino]methyl]-4-pyridinyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H30 N4 O . 2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 443926-06-5
CMF C32 H30 N4 O

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:125098

L31 ANSWER 4 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **443926-06-5** REGISTRY
CN Benzonitrile, 4-[[3-[[[(4S)-2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-3-oxo-1H-2-benzazepin-4-yl]amino]methyl]-4-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H30 N4 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:125098

L31 ANSWER 5 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **443304-56-1** REGISTRY
CN Benzonitrile, 4-[[3-[[[3-(2-methylphenyl)-2-cyclohepten-1-yl]amino]methyl]-4-pyridinyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H29 N3 . 2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 443304-55-0
CMF C28 H29 N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:109277

L31 ANSWER 6 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **443304-29-8** REGISTRY
CN Benzonitrile, 4-[[3-[[[3-[3-(phenylthio)phenyl]-2-cyclohepten-1-yl]amino]methyl]-4-pyridinyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H31 N3 S . 2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 443304-28-7
CMF C33 H31 N3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:109277

L31 ANSWER 7 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **439103-24-9** REGISTRY
CN 3-Pyridinecarboxamide, N-[2-[[(3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-ethyltetradecahydro-8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-9-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-2H-furo[2,3-c]oxacyclotetradecin-3-yl]amino]-2-oxoethyl]-2-[(4-methylphenyl)thio]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C47 H66 N4 O12 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:63420

L31 ANSWER 8 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN

RN **420847-48-9** REGISTRY
CN 3-Pyridinecarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2-[(4-methylphenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H22 N4 O2 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:355242

L31 ANSWER 9 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **346669-15-6** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-methylphenyl)thio]-N-[1-methyl-2-[[3-(trifluoromethyl)benzoyl]amino]ethyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H22 F3 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:76694

L31 ANSWER 10 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **346669-13-4** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[1-methyl-2-[[3-(trifluoromethyl)benzoyl]amino]ethyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C23 H19 Cl F3 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:76694

L31 ANSWER 11 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **333990-73-1** REGISTRY
CN 4-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-N-[3-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]propyl]-1-[[2-[(4-methylphenyl)thio]-3-pyridinyl]carbonyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-(3,4-Dichlorophenyl)-N-[3-[4-(4-fluorobenzyl)-1-piperidinyl]propyl]-1-[2-(4-methylphenylthio)-3-pyridylcarbonyl]-4-piperidinecarboxamide trifluoroacetate (1:3)
MF C40 H43 Cl2 F N4 O2 S . 3 C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 333990-72-0
CMF C40 H43 Cl2 F N4 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:295739

L31 ANSWER 12 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **325162-30-9** REGISTRY
CN Benzoic acid, 3-[[[3-[(4-chlorophenyl)methyl]-4-pyridinyl]methylene]amino]-2-methoxy- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-[[[3-(4-Chlorobenzyl)-4-pyridyl]methylene]amino]salicylic acid methyl ester
FS 3D CONCORD
MF C21 H17 Cl N2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:163045

L31 ANSWER 13 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **325162-28-5** REGISTRY
CN Benzoic acid, 3-[[[3-[(4-chlorophenyl)methyl]-4-pyridinyl]methyl]amino]-2-hydroxy-, methyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-[[[3-(4-Chlorobenzyl)-4-pyridyl]methyl]amino]salicylic acid methyl ester
FS 3D CONCORD
MF C21 H19 Cl N2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:163045

L31 ANSWER 14 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **325162-26-3** REGISTRY
CN 2H-1,4-Benzoxazine-8-carboxylic acid, 4-[[3-[(4-chlorophenyl)methyl]-4-pyridinyl]methyl]-3,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-[[3-(4-Chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxylic acid methyl ester
FS 3D CONCORD
MF C23 H21 Cl N2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:163045

L31 ANSWER 15 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **325162-23-0** REGISTRY
CN 2H-1,4-Benzoxazine-8-carboxylic acid, 4-[[3-[(4-chlorophenyl)methyl]-4-pyridinyl]methyl]-3,4-dihydro-, sodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-[[3-(4-Chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxylic acid sodium salt
MF C22 H19 Cl N2 O3 . Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:163045

L31 ANSWER 16 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **325162-21-8** REGISTRY
CN L-Tyrosine, N-[[4-[[3-[(4-chlorophenyl)methyl]-4-pyridinyl]methyl]-3,4-dihydro-2H-1,4-benzoxazin-8-yl]carbonyl]-O-methyl-, methyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[1(S)-Methoxycarbonyl-2-(4-methoxyphenyl)ethyl]-4-[[3-(4-chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide
FS STEREOSEARCH
MF C33 H32 Cl N3 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:163045

L31 ANSWER 17 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **325162-05-8** REGISTRY
CN 2H-1,4-Benzoxazine-8-carboxamide, N-[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-4-[[3-[(4-chlorophenyl)methyl]-4-pyridinyl]methyl]-3,4-dihydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:
CN N-[1(S)-Carbamoyl-2-(4-methoxyphenyl)ethyl]-4-[[3-(4-chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide oxalate
FS STEREOSEARCH
MF C32 H31 Cl N4 O4 . C2 H2 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 325160-94-9
CMF C32 H31 Cl N4 O4

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:163045

L31 ANSWER 18 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **325160-94-9** REGISTRY
CN 2H-1,4-Benzoxazine-8-carboxamide, N-[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-4-[[3-[(4-chlorophenyl)methyl]-4-pyridinyl]methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[1-(S)-Carbamoyl-2-(4-methoxyphenyl)ethyl]-4-[[3-(4-chlorobenzyl)-4-pyridyl]methyl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide
FS STEREOSEARCH
MF C32 H31 Cl N4 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:163045

L31 ANSWER 19 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **306999-01-9** REGISTRY
CN 3-Quinolinecarbonitrile, 4-[[4-[(3-cyano-2-pyridinyl)thio]phenyl]amino]-6,7-dimethoxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H17 N5 O2 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 133:362712

L31 ANSWER 20 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **300855-81-6** REGISTRY
CN Cyclohexanol, 2-[[[2-amino-5-[(4-chlorophenyl)thio]-4-pyrimidinyl]methyl]amino]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H21 Cl N4 O S
SR CA
LC STN Files: CA, CAPLUS

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 133:296442

L31 ANSWER 21 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **300581-67-3** , REGISTRY
CN Vancomycin, N3''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-49-[[2-[(4-chlorophenyl)thio]-3-pyridinyl]carbonyl]-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C84 H77 Cl4 N9 O24 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 133:296658

L31 ANSWER 22 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **259673-23-9** REGISTRY
CN Pyrazineacetic acid, 3-[(3-fluorophenyl)thio]-.alpha.-(methoxyimino)-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H12 F N3 O3 S
SR CA

LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:180599

L31 ANSWER 23 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **259673-20-6** REGISTRY
CN Pyrazineacetic acid, 3-[(3-chlorophenyl)thio]-.alpha.-(methoxyimino)-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H12 Cl N3 O3 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:180599

L31 ANSWER 24 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **259673-17-1** REGISTRY
CN Pyrazineacetic acid, 3-[(3-bromophenyl)thio]-.alpha.-(methoxyimino)-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H12 Br N3 O3 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:180599

L31 ANSWER 25 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **259673-08-0** REGISTRY
CN Pyrazineacetic acid, .alpha.-(methoxyimino)-3-[(3-methylphenyl)thio]-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H15 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:180599

L31 ANSWER 26 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **245322-47-8** REGISTRY
CN Glycine, N-[[2-[(4-methylphenyl)thio]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H14 N2 O3 S
SR CAS Client Services
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:63420

L31 ANSWER 27 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **240418-34-2** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[2-hydroxy-3-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD

MF C28 H33 Cl N4 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:424

REFERENCE 2: 131:184970

L31 ANSWER 28 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **232617-65-1** REGISTRY
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(4-methylphenyl)thio]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H24 Cl2 N2 O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:116520

L31 ANSWER 29 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **228095-95-2** REGISTRY
CN Piperazine, 1-(2-methoxyphenyl)-4-[[5-(2-methoxyphenyl)-2-[(4-methoxyphenyl)thio]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C31 H33 N3 O3 S
SR CA

LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:58848

L31 ANSWER 30 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **228095-92-9** REGISTRY
CN Piperazine, 1-(2-methoxyphenyl)-4-[[2-[(4-methoxyphenyl)thio]-5-phenyl-3-pyridinyl]methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)
MF C30 H31 N3 O2 S . C2 H2 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 228095-91-8
CMF C30 H31 N3 O2 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:58848

L31 ANSWER 31 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **228095-91-8** REGISTRY
CN Piperazine, 1-(2-methoxyphenyl)-4-[[2-[(4-methoxyphenyl)thio]-5-phenyl-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C30 H31 N3 O2 S
CI COM
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:58848

L31 ANSWER 32 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **227449-85-6** REGISTRY
CN 5-Pyrimidinecarboxamide, 2-[(2-aminoethyl)amino]-4-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H19 N5 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:44844

L31 ANSWER 33 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **227449-77-6** REGISTRY
CN 5-Pyrimidinecarboxamide, 2-[(2-aminoethyl)amino]-4-[[3-(trifluoromethyl)phenyl]thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H14 F3 N5 O S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:44844

L31 ANSWER 34 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **227449-65-2** REGISTRY
CN 5-Pyrimidinecarboxamide, 4-[(3-methoxyphenyl)methyl]-2-(methylthio)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H15 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:44844

L31 ANSWER 35 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **227449-54-9** REGISTRY
CN 5-Pyrimidinecarboxamide, 2-(1H-benzotriazol-1-yloxy)-4-[[3-(trifluoromethyl)phenyl]thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H11 F3 N6 O2 S

SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:44844

L31 ANSWER 36 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **227327-82-4** REGISTRY
CN 3-Pyridinecarboxamide, 2-[[4-[3-(dimethylamino)propoxy]phenyl]thio]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)
MF C28 H37 N3 O2 S . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



●2 HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:58652

L31 ANSWER 37 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **227327-80-2** REGISTRY
CN Acetic acid, [4-[[3-[[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-pyridinyl]thio]phenoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H28 N2 O4 S
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:58652

L31 ANSWER 38 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **227327-73-3** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-methoxyphenyl)thio]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H28 N2 O2 S
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:58652

L31 ANSWER 39 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **227327-50-6** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-methylphenyl)thio]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H28 N2 O S
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:58652

L31 ANSWER 40 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224822-03-1** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-[2-(1-methylethoxy)phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H22 Cl N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 41 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224814-98-6** REGISTRY
CN 3-Pyridinecarboxamide, N-[6-(4-bromophenoxy)-3-pyridinyl]-2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H15 Br Cl N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 42 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224813-98-3** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-(3-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H15 Cl N4 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 43 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224812-92-4** REGISTRY
CN 3-Pyridinecarboxamide, N-[6-(4-chloro-3,5-dimethylphenoxy)-3-pyridinyl]-2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H19 Cl2 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 44 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224811-52-3** REGISTRY
CN 3-Pyridinecarboxamide, N-[6-(4-chloro-2-cyclohexylphenoxy)-3-pyridinyl]-2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
MF C29 H25 Cl2 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 45 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224810-57-5** REGISTRY
CN 3-Pyridinecarboxamide, N-[6-(4-chloro-3-methylphenoxy)-3-pyridinyl]-2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H17 Cl2 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 46 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224809-64-7** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-(2,4-dichlorophenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H14 Cl3 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 47 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224808-46-2** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-(2,6-dichlorophenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H14 Cl3 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 48 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224807-56-1** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H15 Cl F3 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 49 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224806-63-7** REGISTRY
CN 3-Pyridinecarboxamide, N-[6-[3,5-bis(1-methylethyl)phenoxy]-3-pyridinyl]-2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C29 H28 Cl N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 50 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224805-72-5** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-(2,3-dimethylphenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H20 Cl N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 51 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224804-80-2** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-[4-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H24 Cl N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 52 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224803-75-2** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-[4-(methylthio)phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H18 Cl N3 O2 S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 53 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224802-65-7** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-(2,4-difluorophenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H14 Cl F2 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 54 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224801-77-8** REGISTRY
CN 3-Pyridinecarboxamide, N-[6-(4-chlorophenoxy)-3-pyridinyl]-2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H15 Cl2 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 55 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224800-84-4** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-(4-fluorophenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H15 Cl F N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 56 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224799-37-5** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[6-(4-methoxyphenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H18 Cl N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 57 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **224798-42-9** REGISTRY
CN 3-Pyridinecarboxamide, N-[6-(4-chloro-2,5-dimethylphenoxy)-3-pyridinyl]-2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H19 Cl2 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:352186

L31 ANSWER 58 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **220221-36-3** REGISTRY
CN 3-Pyridinecarboxamide, N-[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]-2-[(4-methylphenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H35 N5 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:358745

REFERENCE 2: 136:15226

REFERENCE 3: 134:237682

REFERENCE 4: 130:153469

L31 ANSWER 59 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **219919-15-0** REGISTRY
CN Benzonitrile, 4-[[4-[[4-(3-chlorophenyl)-2,3-dioxo-1-piperazinyl]methyl]-3-pyridinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C24 H19 Cl N4 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (197912-97-3)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:125091

L31 ANSWER 60 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **219552-94-0** REGISTRY
CN Benzonitrile, 4-[[4-[[(2S)-4-(3-chlorophenyl)-2-[2-(methylsulfonyl)ethyl]-5-oxo-1-piperazinyl]methyl]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H27 Cl N4 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:95565

L31 ANSWER 61 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **198084-17-2** REGISTRY
CN Benzonitrile, 4-[[4-[[(2S)-2-butyl-5-oxo-4-(2,2,2-trifluoroethyl)-1-piperazinyl]methyl]-3-pyridinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzonitrile, 4-[[4-[[2-butyl-5-oxo-4-(2,2,2-trifluoroethyl)-1-piperazinyl]methyl]-3-pyridinyl]methyl]-, dihydrochloride, (S)-
FS STEREOSEARCH
MF C24 H27 F3 N4 O . 2 Cl H
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



●2 HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:299463

REFERENCE 2: 127:346413

L31 ANSWER 62 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197912-97-3** REGISTRY
CN Benzonitrile, 4-[[4-[[4-(3-chlorophenyl)-2,3-dioxo-1-piperazinyl]methyl]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H19 Cl N4 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:331505

L31 ANSWER 63 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197911-53-8** REGISTRY
CN Benzonitrile, 4-[[4-[[4-(3-chlorophenyl)-2,5-dioxo-1-piperazinyl]methyl]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C24 H19 Cl N4 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:331509

L31 ANSWER 64 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197911-38-9** REGISTRY
CN Benzonitrile, 4-[[4-[[4-(3-chlorophenyl)-2,5-dioxo-1-piperazinyl]methyl]-3-pyridinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C24 H19 Cl N4 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (197911-53-8)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:331509

L31 ANSWER 65 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197853-33-1** REGISTRY
CN Benzonitrile, 4-[[4-[[4-(3-chlorophenyl)-2-oxo-1-piperazinyl]methyl]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H21 Cl N4 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:237591

REFERENCE 2: 127:331503

L31 ANSWER 66 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197853-30-8** REGISTRY
CN Benzonitrile, 4-[[4-[[4-(3-chlorophenyl)-2-oxo-1-piperazinyl]methyl]-3-pyridinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C24 H21 Cl N4 O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (197853-33-1)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:237591

REFERENCE 2: 127:331503

L31 ANSWER 67 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197786-45-1** REGISTRY
CN Benzonitrile, 4-[[4-[(methylamino)methyl]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(4-Cyanobenzyl)-4-[(methylamino)methyl]pyridine
FS 3D CONCORD
MF C15 H15 N3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:122662

REFERENCE 2: 127:318953

L31 ANSWER 68 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197786-35-9** REGISTRY
CN Benzenemethanesulfonamide, 3-chloro-N-[[3-[(4-cyanophenyl)methyl]-4-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H18 Cl N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:122662

REFERENCE 2: 127:318953

L31 ANSWER 69 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197786-28-0** REGISTRY
CN Benzenemethanesulfonamide, 3-chloro-N-[[3-[(4-cyanophenyl)methyl]-4-pyridinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H20 Cl N3 O2 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:122662

REFERENCE 2: 127:318953

L31 ANSWER 70 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197786-21-3** REGISTRY
CN Benzenemethanesulfonamide, 3-chloro-N-[[3-[(4-cyanophenyl)methyl]-4-pyridinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)
MF C22 H20 Cl N3 O2 S . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (197786-28-0)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:122662

REFERENCE 2: 127:318953

L31 ANSWER 71 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **182437-80-5** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[1-[4-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)
MF C37 H36 Cl F3 N4 O2 S . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (182432-31-1)

PAGE 1-A



PAGE 2-A



●2 HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 125:275663

L31 ANSWER 72 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **182436-32-4** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[1-[4-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C37 H36 Cl F3 N4 O2 S . Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (182432-31-1)

PAGE 1-A



PAGE 2-A



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 125:275663

L31 ANSWER 73 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **182432-31-1** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-[1-[4-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-4-piperidinyl]-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C37 H36 Cl F3 N4 O2 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 128:154011

REFERENCE 2: 125:275663

L31 ANSWER 74 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **159970-99-7** REGISTRY
CN Piperazine, 1-methyl-4-[[4-[(3-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C23 H23 N5 O3 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
CRN (116904-78-0)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 122:55996

L31 ANSWER 75 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **153143-99-8** REGISTRY
CN 3-Pyridinecarbonyl azide, 2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H7 Cl N4 O S
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 120:152980

L31 ANSWER 76 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **145769-31-9** REGISTRY
CN 3-Pyridinecarbonitrile, 5-[2-(2,6-dichlorophenyl)ethenyl]-2-[(4-nitrophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H11 Cl2 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 118:147572

L31 ANSWER 77 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **143469-45-8** REGISTRY
CN Pyrazinecarbonitrile, 5,6-diamino-3-[(4-methylphenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H11 N5 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 117:171474

L31 ANSWER 78 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **143469-44-7** REGISTRY
CN Pyrazinecarbonitrile, 5,6-diamino-3-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C11 H8 Cl N5 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 117:171474

L31 ANSWER 79 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN

RN **141987-66-8** REGISTRY
CN 3,5-Pyridinedicarbonitrile, 2-amino-6-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H10 N4 S
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 117:26413

L31 ANSWER 80 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **135956-47-7** REGISTRY
CN 3-Pyridinecarboxamide, N-[2-(3,4-dichlorophenyl)-4-[4-(phenylmethyl)-1-piperidinyl]butyl]-2-[(3,5-dimethoxyphenyl)thio]-, dihydrochloride (9CI) (CA INDEX NAME)
MF C36 H39 Cl2 N3 O3 S . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:279818

L31 ANSWER 81 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **135629-60-6** REGISTRY
CN 1,2-Ethanediamine, N'-[[2-[(4-bromophenyl)thio]-7-chloro-8-methyl-3-quinolinyl]methyl]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)
MF C23 H27 Br Cl N3 S . Cl H
SR CA
LC STN Files: CA, CAPLUS



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:106008

L31 ANSWER 82 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **135629-48-0** REGISTRY
CN 1,2-Ethanediamine, N'-[[2-[(4-bromophenyl)thio]-7-chloro-8-methyl-3-quinolinyl]methylene]-N,N-diethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H25 Br Cl N3 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:106008

L31 ANSWER 83 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **135439-27-9** REGISTRY
CN Benzoic acid, 4-[2-[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H15 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:92864

L31 ANSWER 84 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **128478-59-1** REGISTRY
CN 2-Quinoxalinecarbonitrile, 3-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H11 N3 O2 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 113:78340

L31 ANSWER 85 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **128169-38-0** REGISTRY
CN Pyrazinecarbonitrile, 3-[[4-(4-fluorophenoxy)phenyl]thio]-5,6-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H14 F N3 O S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 113:59240

L31 ANSWER 86 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **128169-37-9** REGISTRY
CN Pyrazinecarbonitrile, 5,6-dimethyl-3-[[4-(4-methylphenoxy)phenyl]thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H17 N3 O S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 113:59240

L31 ANSWER 87 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **116904-78-0** REGISTRY
CN Piperazine, 1-methyl-4-[[4-[(3-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)
MF C23 H23 N5 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 109:170451

L31 ANSWER 88 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **116904-66-6** REGISTRY
CN Pyrimidine, 5-[(4-methyl-1-piperazinyl)methyl]-4-[(3-nitrophenyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H25 N5 O2
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 122:55996

REFERENCE 2: 109:170451

L31 ANSWER 89 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **116904-65-5** REGISTRY
CN Pyrimidine, 5-[(4-methyl-1-piperazinyl)methyl]-4-[(4-nitrophenyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H25 N5 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 122:55996

REFERENCE 2: 109:170451

L31 ANSWER 90 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **116904-35-9** REGISTRY
CN Piperazine, 1-methyl-4-[[4-[(4-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)
MF C23 H23 N5 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 122:55996

REFERENCE 2: 109:170451

L31 ANSWER 91 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **116904-34-8** REGISTRY
CN Piperazine, 1-methyl-4-[[4-[(3-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)
MF C23 H23 N5 O3 . x Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (116904-78-0)



●x HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 109:170451

L31 ANSWER 92 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **105580-43-6** REGISTRY
CN Benzoic acid, 4-[2-[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]-1-methylethenyl]-, 1,1-dimethylethyl ester, (Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H23 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 107:176424

REFERENCE 2: 106:33470

L31 ANSWER 93 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **105580-42-5** REGISTRY
CN Benzoic acid, 4-[2-[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]-1-methylethenyl]-, 1,1-dimethylethyl ester, (E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H23 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 107:176424

REFERENCE 2: 106:33470

L31 ANSWER 94 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **105580-40-3** REGISTRY
CN Benzoic acid, 4-[2-[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]ethenyl]-, 1,1-dimethylethyl ester, (Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H21 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 106:33470

L31 ANSWER 95 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **105580-39-0** REGISTRY
CN Benzoic acid, 4-[2-[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]ethenyl]-, 1,1-dimethylethyl ester, (E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H21 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 106:33470

L31 ANSWER 96 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **105580-38-9** REGISTRY
CN Phosphonium, tributyl[[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]methyl]-, bromide (9CI) (CA INDEX NAME)
MF C25 H35 N3 O2 P S . Br
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 107:176424

REFERENCE 2: 106:33470

L31 ANSWER 97 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **101569-95-3** REGISTRY
CN 2-Quinoxalinecarboxamide, 3-p-methoxybenzyl- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 N3 O2
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 55:38071

L31 ANSWER 98 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **97936-34-0** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-(2,6-dimethylphenyl)-
(9CI) (CA INDEX NAME)
MF C20 H17 Cl N2 O S
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 103:104912

L31 ANSWER 99 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **97936-27-1** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-2-pyridinyl- (9CI) (CA
INDEX NAME)
FS 3D CONCORD
MF C17 H12 Cl N3 O S
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 103:104912

L31 ANSWER 100 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **97936-26-0** REGISTRY
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H12 Cl N3 O S2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 103:104912

L31 ANSWER 101 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **97936-25-9** REGISTRY
CN 3-Pyridinecarboxamide, 2-[(4-chlorophenyl)thio]-N-2-thiazolyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H10 Cl N3 O S2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 103:104912

L31 ANSWER 102 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **95693-78-0** REGISTRY
CN Benzoic acid, 4-[2-[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]ethenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H21 N3 O4 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 107:176424

REFERENCE 2: 103:6676

L31 ANSWER 103 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **95693-77-9** REGISTRY
CN Phosphonium, [[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]methyl]triphenyl-, bromide (9CI) (CA INDEX NAME)
MF C31 H23 N3 O2 P S . Br
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



● Br⁻

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 118:147572

REFERENCE 2: 107:176424

REFERENCE 3: 106:33470

REFERENCE 4: 103:6676

L31 ANSWER 104 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **95674-62-7** REGISTRY
CN Benzoic acid, 4-[2-[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]ethenyl]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H17 N3 O4 S

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 106:33470

REFERENCE 2: 103:6676

L31 ANSWER 105 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **88566-70-5** REGISTRY
CN 3-Pyridinecarbonitrile, 2-[(4-nitrophenyl)thio]-5-(tribromomethyl)- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C13 H6 Br3 N3 O2 S
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 100:68665

L31 ANSWER 106 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **88553-20-2** REGISTRY
CN Pyridinium, 1-[[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]methyl]- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C18 H13 N4 O2 S
CI COM
LC STN Files: CA, CAPLUS, TOXCENTER



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 100:68665

L31 ANSWER 107 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **88553-19-9** REGISTRY
CN 3-Pyridinecarbonitrile, 5-(bromomethyl)-2-[(4-nitrophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H8 Br N3 O2 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 106:33470

REFERENCE 2: 103:6676

REFERENCE 3: 100:68665

L31 ANSWER 108 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **87373-87-3** REGISTRY
CN 3-Pyridinecarbonitrile, 5-[[[4-(dimethylamino)phenyl]oxidoimino]methyl]-2-[(4-nitrophenyl)thio]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Pyridinecarbonitrile, 5-[[[4-(dimethylamino)phenyl]imino]methyl]-2-[(4-nitrophenyl)thio]-, N-oxide
FS 3D CONCORD
MF C21 H17 N5 O3 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 101:55505

REFERENCE 2: 100:103829

L31 ANSWER 109 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **87373-64-6** REGISTRY
CN 3-Pyridinecarbonitrile, 5-(dimethoxymethyl)-2-[(4-nitrophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD

MF C15 H13 N3 O4 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 101:55505

REFERENCE 2: 100:103829

REFERENCE 3: 100:68665

L31 ANSWER 110 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **87373-63-5** REGISTRY
CN 3-Pyridinecarbonitrile, 5-formyl-2-[(4-nitrophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H7 N3 O3 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 101:55505

REFERENCE 2: 100:103829

REFERENCE 3: 100:68665

L31 ANSWER 111 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **87373-62-4** REGISTRY
CN Pyridinium, 1-[[5-cyano-6-[(4-nitrophenyl)thio]-3-pyridinyl]methyl]-, bromide (9CI) (CA INDEX NAME)
MF C18 H13 N4 O2 S . Br
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)
CRN (88553-20-2)



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 101:55505

REFERENCE 2: 100:103829

L31 ANSWER 112 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **87373-61-3** REGISTRY
CN 3-Pyridinecarbonitrile, 5-(dibromomethyl)-2-[(4-nitrophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H7 Br2 N3 O2 S
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 101:55505

REFERENCE 2: 100:103829

REFERENCE 3: 100:68665

L31 ANSWER 113 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **87373-60-2** REGISTRY
CN 3-Pyridinecarbonitrile, 5-methyl-2-[(4-nitrophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H9 N3 O2 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 106:33470

REFERENCE 2: 103:6676

REFERENCE 3: 101:55505

REFERENCE 4: 100:103829

REFERENCE 5: 100:68665

L31 ANSWER 114 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **51723-90-1** REGISTRY
CN 3-Pyridineacetonitrile, 2-[[4-(1-methylethyl)phenyl]thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H16 N2 S
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 85:21451

REFERENCE 2: 80:82882

L31 ANSWER 115 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **51723-89-8** REGISTRY
CN 3-Pyridineacetonitrile, 2-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H9 Cl N2 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMCATS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 85:21451

REFERENCE 2: 80:82882

L31 ANSWER 116 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **35620-70-3** REGISTRY
CN 3-Pyridinecarbonitrile, 2-[[3-(trifluoromethyl)phenyl]thio]- (9CI) (CA

INDEX NAME)
FS 3D CONCORD
MF C13 H7 F3 N2 S
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 76:126788

L31 ANSWER 117 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **31309-29-2** REGISTRY
CN 3-Pyridinecarbonitrile, 2-[(4-methylphenyl)thio]-5-nitro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Nicotinonitrile, 5-nitro-2-(p-tolylthio)- (8CI)
FS 3D CONCORD
MF C13 H9 N3 O2 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 77:88314

REFERENCE 2: 74:99891

L31 ANSWER 118 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **31309-28-1** REGISTRY
CN 3-Pyridinecarbonitrile, 2-[(3-methylphenyl)thio]-5-nitro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Nicotinonitrile, 5-nitro-2-(m-tolylthio)- (8CI)
FS 3D CONCORD
MF C13 H9 N3 O2 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 77:88314

REFERENCE 2: 74:99891

L31 ANSWER 119 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **23773-91-3** REGISTRY
CN 2-Quinoxalinecarbonitrile, 3-(p-methoxybenzyl)- (8CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H13 N3 O
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 71:101819

L31 ANSWER 120 OF 120 REGISTRY COPYRIGHT 2004 ACS on STN
RN **955-63-5** REGISTRY
CN Nicotinonitrile, 2-[(p-chlorophenyl)thio]-6-methyl- (7CI, 8CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H9 Cl N2 S
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 62:51669